pyrimethamine has been researched along with Parasitemia in 185 studies
Maloprim: contains above 2 cpds
Parasitemia: The presence of parasites (especially malarial parasites) in the blood. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV." | 9.27 | Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018) |
| "The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa." | 9.27 | Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018) |
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 9.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 9.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "Whether administration of folic acid to children with malaria anemia is helpful is controversial." | 9.12 | Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 9.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 9.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 9.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone." | 9.11 | A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 9.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| ", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study." | 9.09 | Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999) |
| "Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy." | 9.01 | A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 8.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 8.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy." | 8.02 | Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021) |
| "Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa." | 7.79 | High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013) |
| "Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)." | 7.78 | Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012) |
| "To assess the effect of intermittent preventive treatment with sulfadoxine and pyrimethamine (IPT-SP) on placental parasitemia and maternal and perinatal outcome." | 7.77 | Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. ( Akubuo, KK; Aziken, ME; Gharoro, EP, 2011) |
| "Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown." | 7.77 | Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011) |
| "The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa." | 7.77 | Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 7.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)." | 7.74 | Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 7.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| "In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy." | 7.69 | Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997) |
| "We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth." | 7.30 | The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023) |
| "Intermittent preventive treatment of malaria during pregnancy (IPTp) with dihydroartemisinin-piperaquine (DP) provides greater protection from placental malaria than sulfadoxine-pyrimethamine (SP)." | 5.51 | The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria. ( Andronescu, LR; Chinkhumba, J; Gutman, JR; Kachepa, W; Kachingwe, M; Laufer, MK; Liang, Y; Mathanga, DP; Peterson, I; Sharma, A, 2022) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 5.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| " There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18." | 5.37 | The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011) |
| "Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp)." | 5.30 | A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women. ( Benjamin, JM; Davis, TME; Kasian, B; Kong, C; Laman, M; Moore, BR; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, S; Tobe, R; Yadi, G, 2019) |
| "To compare the effectiveness of mefloquine and sulphadoxine-pyrimethamine as intermittent preventive therapy for malaria among pregnant women with HIV." | 5.27 | Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria. ( Abdus-Salam, R; Akinyotu, O; Arowojolu, A; Bello, F, 2018) |
| "The spread of SP resistance may compromise the effectiveness of intermittent preventive treatment of malaria in pregnancy (MiP) with sulfadoxine-pyrimethamine (IPTp-SP) across Africa." | 5.27 | Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria. ( Berens-Riha, N; Esu, E; Loescher, T; Meremikwu, M; Nwachuku, N; Pritsch, M, 2018) |
| "Intermittent treatment with sulfadoxine-pyrimethamine is widely recommended for the prevention of malaria in pregnant women in Africa." | 5.22 | Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. ( Ategeka, J; Awori, P; Charlebois, ED; Clark, TD; Dorsey, G; Feeney, ME; Havlir, DV; Jagannathan, P; Kakuru, A; Kamya, MR; Muehlenbachs, A; Muhindo, MK; Nakalembe, M; Natureeba, P; Nayebare, P; Olwoch, P; Opira, B; Rizzuto, G, 2016) |
| "The effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of malaria in pregnancy (IPTp) might be compromised by high prevalence of resistance-associated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations." | 5.20 | In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi. ( Abdallah, J; Gutman, J; Iriemenam, NC; Mathanga, DP; Mwandama, D; Shi, YP; Skarbinski, J; Wiegand, RE, 2015) |
| "To compare the efficacy of monthly SP presumptive treatment, versus weekly chloroquine for malaria prophylaxis in children attending the Sickle Cell Clinic, Mulago Hospital." | 5.14 | Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial. ( Nakiboneka, D; Nakibuuka, V; Ndeezi, G; Ndugwa, CM; Tumwine, JK, 2009) |
| "The use of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment in pregnancy (IPTp) is threatened by the spread of resistance to SP." | 5.13 | A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana. ( Affipunguh, PK; Bruce, J; Chandramohan, D; Clerk, CA; Greenwood, B; Hodgson, A; Mensah, N, 2008) |
| "The main objective of the study was to assess the impact of a community-based delivery system of intermittent preventive treatment (IPT) for malaria in pregnancy with sulfadoxine-pyrimethamine (SP) on access, parasitemia, anemia and low birth weight as primary outcome measures." | 5.13 | Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda. ( Bygbjerg, I; Magnussen, P; Mbonye, AK, 2008) |
| "Whether administration of folic acid to children with malaria anemia is helpful is controversial." | 5.12 | Folic acid treatment of Zambian children with moderate to severe malaria anemia. ( Bennett, S; Fielding, K; Greenwood, B; Malunga, P; Mulenga, M; Shulman, C; Thuma, P, 2006) |
| "We investigated the ability of intermittent preventive treatment in pregnancy (IPTp) with sulphadoxine/pyrimethamine to prevent anaemia and low birthweight in Gambian multigravidae." | 5.12 | A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae. ( Balajo, B; Dunyo, S; Greenwood, B; Mbaye, A; Milligan, P; Richardson, K; Shulman, C; Walraven, G, 2006) |
| "Few studies have documented the effectiveness in west Africa of intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine (SP) in pregnancy." | 5.12 | A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. ( Madaki, JK; Sagay, AS; Thacher, TD; Tukur, IU, 2007) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) is currently the recommended regimen for prevention of malaria in pregnancy in endemic areas." | 5.12 | Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria. ( Fadero, FF; Falade, CO; Hamer, DH; Mokuolu, OA; Salako, LA; Yusuf, BO, 2007) |
| "The treatment efficacy and effects of artemether-lumefantrine (AL) and amodiaquine-sulfalene-pyrimethamine (ASP) on gametocyte carriage were evaluated in 181 children < or = 10 years of age with uncomplicated Plasmodium falciparum malaria randomized to receive either drug combination." | 5.12 | Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria. ( Adedeji, AA; Fateye, BA; Fehintola, FA; Folarin, OA; Gbotosho, GO; Happi, CT; Sowunmi, A; Tambo, E, 2007) |
| "The World Health Organization advocates 2-3 doses of sulfadoxine-pyrimethamine (SP) for intermittent preventive treatment of malaria (SP IPTp)." | 5.12 | Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mukwamataba, D; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "In Mali, IPT with SP appears more efficacious than weekly chloroquine chemoprophylaxis in preventing malaria during pregnancy." | 5.11 | Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali. ( Coulibaly, D; Doumbo, O; Doumtabe, D; Kayentao, K; Keita, AS; Kodio, M; Maiga, B; Maiga, H; Mungai, M; Newman, RD; Ongoiba, A; Parise, ME, 2005) |
| "The study examined the efficacy of chloroquine (CQ), amodiaquine (AQ) and sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated Plasmodium falciparum malaria in Ghana." | 5.11 | A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana. ( Amankwa, J; Ansah, NA; Ansah, P; Anto, F; Anyorigiya, T; Atuguba, F; Hodgson, A; Mumuni, G; Oduro, AR, 2005) |
| "In an open, randomized, clinical trial, conducted in New Halfa, eastern Sudan, in September-October 2004, the efficacies and adverse effects of artesunate plus sulfadoxine-pyrimethamine (SP), in the treatment of uncomplicated, Plasmodium falciparum malaria, were compared with those of SP alone." | 5.11 | A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan. ( A-Elbasit, IE; Adam, I; Elbashir, MI; Idris, SM; Malik, EM, 2005) |
| "To evaluate the effects of intermittent preventive treatment for malaria in infants (IPTi) with sulfadoxine-pyrimethamine in an area of intense, seasonal transmission." | 5.11 | Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. ( Amponsa-Achiano, K; Awine, T; Baiden, R; Binka, F; Carneiro, I; Chandramohan, D; Greenwood, B; Hodgson, A; Jaffar, S; Mensah, N; Owusu-Agyei, S, 2005) |
| " The authors recommend that the treatment to be used in Abie must be firstly amodiaquine followed by sulfadoxine-pyrimethamine in cases where there is persistent asymptomatic parasitemia." | 5.11 | [Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire]. ( Adjetey, TA; Affoumou, GB; Barro-Kiki, P; Kone, M; Loukou, DD; Menan, EI; Nebavi, NG; Yavo, W, 2005) |
| "We evaluated gametocyte carriage and intensities of gametocytaemia in 710 children presenting with acute, symptomatic, uncomplicated Plasmodium falciparum malaria who were treated with various antimalarial drug regimens: chloroquine (CQ); chloroquine plus chlorpheniramine, a histamine H1 receptor antagonist that reverses CQ resistance in P." | 5.10 | Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs. ( Fateye, BA; Sowunmi, A, 2003) |
| "The efficacy and kinetics of the combination chloroquine plus sulfadoxine-pyrimethamine (CQ + SP), given sequentially and simultaneously, were investigated in 32 patients with acute uncomplicated Plasmodium falciparum malaria in Palawan Island, the Philippines." | 5.10 | Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines. ( Bustos, DG; Diquet, B; Gay, F; Laracas, CJ; Lazaro, JE; Pottier, A; Traore, B, 2002) |
| " 600 children with acute uncomplicated Plasmodium falciparum malaria, aged 6 months to 10 years, at five health centres were randomly assigned pyrimethaminesulphadoxine (25 mg/500 mg) with placebo; pyrimethamine-sulphadoxine plus one dose of artesunate (4mg/kg bodyweight); or pyrimethamine-sulphadoxine plus one dose 4 mg/kg bodyweight artesunate daily for 3 days." | 5.09 | Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial. ( Alloueche, A; Anyalebechi, C; Bojang, K; Coleman, R; Doherty, T; Duraisingh, M; Gosling, R; Greenwood, B; McAdam, K; Milligan, P; Olliaro, P; Pinder, M; Sadiq, A; Targett, G; Ude, JI; von Seidlein, L; Walraven, G; Warhurst, D, 2000) |
| ", Basel Switzerland) (pyrimethamine and sulfadoxine), primaquine in a high dose, and artesunate for treating acute Plasmodium vivax malaria, we conducted a comparative clinical trial of these 3 drugs in an open-label study." | 5.09 | Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. ( Bussaratid, V; Krudsood, S; Looareesuwan, S; Phumratanaprapin, W; Silachamroon, U; Singhasivanon, P; Srivilirit, S; Treeprasertsuk, S; Wilairatana, P, 1999) |
| "We conducted two randomized clinical trials to determine the in vivo efficacy of amodiaquine and sulfadoxine/pyrimethamine in treating Plasmodium falciparum malaria." | 5.09 | In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. ( Ashruf, G; Bennebroek, J; Gikunda, S; Gorissen, E; Kager, PA; Lamboo, M; Mbaruku, G, 2000) |
| "In a randomized trial, a high dosage chloroquine monotherapy (45 mg/kg over 3 days) was compared with combination regimens of sulfadoxine/pyrimethamine and chloroquine/clindamycin for treating Gabonese school children with Plasmodium falciparum malaria." | 5.08 | Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria. ( Bienzle, U; Graninger, W; Kremsner, PG; Metzger, W; Mordmüller, B, 1995) |
| "To define an effective and deliverable antimalarial regimen for use during pregnancy, pregnant women at highest risk of malaria (those in their first or second pregnancy) in an area of Malawi with high transmission of chloroquine (CQ)-resistant Plasmodium falciparum were placed on CQ and/or sulfadoxine-pyrimethamine (SP)." | 5.07 | The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. ( Chitsulo, L; Kazembe, P; Macheso, A; Schultz, LJ; Steketee, RW; Wirima, JJ, 1994) |
| "Intermittent preventive treatment (IPT) with sulphadoxine-pyrimethamine (SP) is recommended for preventing maternal and fetal effects of malaria in pregnancy." | 5.01 | A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy. ( Esu, E; Meremikwu, M; Oduwole, O; Okusanya, BO; Olaleye, A, 2019) |
| "The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| "Mefloquine was more efficacious than sulfadoxine-pyrimethamine in HIV-uninfected women or daily cotrimoxazole prophylaxis in HIV-infected pregnant women for prevention of malaria infection and was associated with lower risk of maternal anaemia, no adverse effects on pregnancy outcomes (such as stillbirths and abortions), and no effects on low birth weight and prematurity." | 4.98 | Mefloquine for preventing malaria in pregnant women. ( Aponte, JJ; González, R; Menéndez, C; Piqueras, M; Pons-Duran, C; Ter Kuile, FO, 2018) |
| " falciparum malaria is treated using Artemisinin-based Combination Therapy (ACT)." | 4.85 | Artemisinin-based combination therapy for treating uncomplicated malaria. ( Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B, 2009) |
| "The World Health Organization recommends the provision of intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) at 4-week intervals from gestational week 13 to delivery in areas of moderate to high malaria transmission intensity." | 4.02 | Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study. ( Bruce, J; Chandramoha, D; Chaponda, EB; Matthew Chico, R; Mharakurwa, S; Michelo, C, 2021) |
| "In 2012 the World Health Organisation (WHO) revised the policy on Intermittent Preventive Treatment with Sulphadoxine Pyrimethamine (IPTp-SP) to at least three doses for improved protection against malaria parasitaemia and its associated effects such as anaemia during pregnancy." | 4.02 | Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study. ( Agyeman, YN; Annor, RB; Newton, S; Owusu-Dabo, E, 2021) |
| "Hence, this study was therefore aimed at evaluating the antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in mice infected with chloroquine sensitive Plasmodium berghei ANKA." | 4.02 | In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA. ( Achidi, EA; Bila, RB; Feugaing Sofeu, DD; Ivo, EP; Taiwe, GS; Tatsinkou Fossi, B; Toukam, LL, 2021) |
| "Pyrimethamine-loaded nanomicelles showed potent antimalarial activity and can be considered as a potential candidate for further examination of their suitability as an antimalarial drug." | 3.96 | A new effective antiplasmodial compound: Nanoformulated pyrimethamine. ( Bide, VZ; Kalani, H; Nematolahy, P; Pestehchian, N; Vafaei, MR; Varshosaz, J; Yousefi, HA, 2020) |
| "A cross-sectional study was conducted of 426 pregnant mothers on IPTp with sulphadoxine-pyrimethamine against malaria who presented in labor, at National Hospital Abuja, Nigeria between January and June 2017." | 3.96 | The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria. ( Agboghoroma, CO; Iregbu, KC; Umemmuo, MU, 2020) |
| " Whether the addition of azithromycin to the monthly sulfadoxine-pyrimethamine plus amodiaquine used for seasonal malaria chemoprevention could reduce mortality and morbidity among African children was unclear." | 3.91 | Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention. ( Barry, A; Cairns, M; Chandramohan, D; Coumare, S; Diarra, M; Dicko, A; Doumbo, O; Greenwood, B; Kuepfer, I; Milligan, P; Nikiema, F; Ouedraogo, JB; Sagara, I; Tapily, A; Thera, I; Tinto, H; Traore, A; Yerbanga, S; Zongo, I, 2019) |
| "Six years after the implementation of intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) in Gabon, its impact on placental malaria and pregnancy outcomes remains unknown." | 3.83 | Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon. ( Ambounda, N; Bouyou-Akotet, MK; Kendjo, E; Kombila, M; Mawili-Mboumba, DP; Moutandou Chiesa, S; Tshibola Mbuyi, ML; Tsoumbou-Bakana, G; Zong, J, 2016) |
| "Despite widespread parasite resistance to sulphadoxine-pyrimethamine (SP) its use for intermittent preventative treatment during pregnancy remains the policy in Benin and throughout most of sub-Saharan Africa." | 3.79 | High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin. ( Alifrangis, M; De Tove, YS; Deloron, P; Doritchamou, J; Luty, AJ; Massougbodji, A; Moussiliou, A; Ndam, NT, 2013) |
| "Antenatal intermittent preventive therapy with 2 doses of sulfadoxine-pyrimethamine (IPTp-SP) is the mainstay of efforts in sub-Saharan Africa to prevent pregnancy-associated malaria (PAM)." | 3.78 | Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. ( Antonia, AL; Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Mwapasa, V; Rogerson, SJ; Taylor, SM; ter Kuile, FO, 2012) |
| "To assess the effect of intermittent preventive treatment with sulfadoxine and pyrimethamine (IPT-SP) on placental parasitemia and maternal and perinatal outcome." | 3.77 | Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria. ( Akubuo, KK; Aziken, ME; Gharoro, EP, 2011) |
| "Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimethamine (SP) intermittent-preventive-therapy (IPTp) for malaria in HIV-infected pregnant women is unknown." | 3.77 | Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi. ( Fitzgerald, M; Kapito-Tembo, A; Meshnick, SR; Mwapasa, V; Phiri, K; van Hensbroek, MB, 2011) |
| "The World Health Organization (WHO) recommends using insecticide-treated mosquito nets (ITNs) and intermittent preventive treatment with sulphadoxine-pyrimethamine (IPT-SP) to prevent malaria in sub-Saharan Africa." | 3.77 | Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire. ( Coffie, PA; Dabis, F; Eholie, SP; Ekouevi, DK; Kanhon, S; Kone, M; Kouakou, F; Menan, H; Sloan, C; Vanga-Bosson, HA, 2011) |
| " They were monitored for development of Plasmodium falciparum malaria, which was treated with chloroquine (CQ) + sulfadoxine-pyrimethamine (SP) and the children followed up for 28 days." | 3.76 | Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study. ( Egwang, TG; Kiyingi, HS; Nannyonga, M, 2010) |
| "To evaluate the impact of a 2-year programme for community-based delivery of sulfadoxine-pyrimethamine (SP) on intermittent preventive treatment during pregnancy coverage, antenatal clinic attendance and pregnancy outcome." | 3.75 | Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi. ( Brabin, BJ; D'Alessandro, U; Gies, S; Kalanda, G; Kazembe, PN; Msyamboza, KP; Savage, EJ, 2009) |
| "Intermittent preventive treatment with sulphadoxine-pyrimethamine (SP) is recommended for reducing the risk of malaria in pregnancy and its consequences on mothers and babies (IPTp-SP)." | 3.74 | Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal. ( Badiane, M; Brasseur, P; Cisse, M; Delenne, H; Olliaro, A; Olliaro, PL; Vaillant, M, 2008) |
| "RBx11160 (OZ277) is a promising antimalarial drug candidate that Ranbaxy Laboratories Limited and Medicines for Malaria Venture (MMV) are currently developing as a fixed combination with piperaquine." | 3.74 | In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models. ( Chollet, J; Santo-Tomas, J; Scheurer, C; Snyder, C; Wittlin, S, 2007) |
| "The World Health Organization recommends that pregnant women in malaria-endemic areas receive >or= 2 doses of intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp/SP) in the second and third trimesters of pregnancy to prevent maternal anemia, placental parasitemia, and low birth weight (LBW)." | 3.73 | Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso. ( Asamoa, K; Bougouma, EC; Cotte, AH; Diarra, A; Konaté, A; Moran, AC; Newman, RD; Ouédraogo, A; Parise, ME; Sirima, SB, 2006) |
| "We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of acute uncomplicated Plasmodium falciparum malaria in children 1-4 years old." | 3.73 | Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes. ( Björkman, A; Hugosson, E; Montgomery, SM; Premji, Z; Troye-Blomberg, M, 2006) |
| "Febrile adults with Plasmodium falciparum parasitemia were treated with sulfadoxine-pyrimethamine and were monitored for 28 days." | 3.73 | HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya. ( Bloland, PB; Hamel, MJ; Kain, KC; Obonyo, CO; Shah, SN; Slutsker, L; Smith, EE, 2006) |
| "The prevalence of infection with malarial parasites and the incidence of anaemia and delivery of infants with low birthweight (LBW) were investigated in 575 Malawian mothers who received one, two or three doses of sulfadoxine-pyrimethamine (SP) during pregnancy." | 3.70 | An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. ( Brabin, BJ; Broadhead, RL; Chimsuku, L; Kazembe, P; Russell, WB; Verhoeff, FH, 1998) |
| " Seventy patients with Plasmodium falciparum malaria were included in a study of resistance to chloroquine and sulfadoxine-pyrimethamine therapy." | 3.70 | Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela. ( Caraballo, A; Rodriguez-Acosta, A, 1999) |
| "The spectrum of antimalarial activity of the new macrolide antibiotic azithromycin was evaluated against blood- and sporozoite-induced infections with a chloroquine-resistant strain of Plasmodium yoelii nigeriensis (N-67) in Swiss mice and with simian parasite Plasmodium cynomolgi B in rhesus monkeys." | 3.70 | Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys. ( Puri, SK; Singh, N, 2000) |
| "As chloroquine resistance spreads across Africa, the dihydrofolate reductase (DHFR) inhibitors pyrimethamine and proguanil are being used as alternative first-line drugs for the treatment and prevention of Plasmodium falciparum malaria." | 3.69 | Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. ( Bouare, M; Djimde, A; Doumbo, O; Plowe, CV; Wellems, TE, 1995) |
| "In 1993, Malawi introduced sulphadoxine-pyrimethamine (SP) for the treatment of uncomplicated, Plasmodium falciparum malaria and became the first country in Africa to abandon chloroquine for first-time therapy." | 3.69 | Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi. ( Brabin, BJ; Kachale, B; Kazembe, P; Masache, P; Van der Kaay, HJ; Verhoeff, FH, 1997) |
| "We assessed the impact of preventive treatment in pregnancy on maternal malaria and fetal growth." | 3.30 | The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial. ( Ashorn, P; Ashorn, U; Cheung, YB; Fan, YM; Hallamaa, L; Kulmala, T; Luntamo, M; Maleta, K; Mangani, C, 2023) |
| "In endemic areas, malaria and its adverse effects in schoolchildren may be prevented by intermittent preventive treatment (IPTsc)." | 2.84 | Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial. ( da Luz, RI; Doua, JY; Lutumba, P; Matangila, JR; Mitashi, P; Van Geertruyden, JP, 2017) |
| "The ongoing development of new antimalarial drugs and the increasing use of controlled human malaria infection (CHMI) studies to investigate their activity in early-stage clinical trials require the development of methods to analyze their pharmacodynamic effect." | 2.80 | Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR. ( Baker, M; Marquart, L; McCarthy, JS; O'Rourke, P, 2015) |
| "Primaquine was well tolerated and could be administered along with an artemisinin combination therapy as the first-line therapy." | 2.78 | Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes. ( Anvikar, A; Juliano, JJ; MacDonald, PD; Meshnick, SR; Mishra, N; Poole, C; Schapira, A; Shah, NK; Srivastava, B; Valecha, N, 2013) |
| " The impact of MDA with the gametocytocidal drug combination sulphadoxine-pyrimethamine (SP) plus artesunate (AS) plus primaquine (PQ, single dose 0." | 2.76 | A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania. ( Bousema, T; Drakeley, C; Gosling, R; Hermsen, R; Masokoto, A; Mosha, F; Mwanziva, C; Okell, L; Sauerwein, R; Semvua, S; Shekalaghe, SA; Teelen, K; ter Braak, R; van den Bijllaardt, W; van den Bosch, S, 2011) |
| " The main outcome measures for safety were incidences of post-treatment clinical and laboratory adverse events." | 2.74 | Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. ( Geita, J; Hiawalyer, G; Hombhanje, FW; Jones, R; Kevau, I; Kuanch, C; Linge, D; Masta, A; Sapuri, M; Saweri, A; Toraso, S, 2009) |
| " Adverse events and clinical and parasitological outcomes were recorded." | 2.73 | A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda. ( D'Alessandro, U; Fanello, CI; Karema, C; Ngamije, D; van Doren, W; Van Overmeir, C, 2007) |
| "Nearly all recurrences were due to new infections." | 2.73 | Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. ( Dokomajilar, C; Dorsey, G; Guiguemde, RT; Ouedraogo, JB; Rosenthal, PJ; Rouamba, N; Tinto, H; Zongo, I, 2007) |
| " However, the optimal dosing regimen in settings in which human immunodeficiency virus (HIV) is highly prevalent among pregnant women remains controversial." | 2.73 | Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women. ( Chalwe, V; Champo, D; Chilengi, R; Gill, CJ; Hamer, DH; Macleod, WB; Mubikayi, L; Mukwamataba, D; Mulele, CK; Mulenga, M; Mwanakasale, V; Mwananyanda, L; Thea, DM, 2007) |
| "The strategy of intermittent preventive treatment of malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) was also addressed." | 2.72 | Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines. ( Al Khaja, KAJ; Sequeira, RP, 2021) |
| "Effective intermittent preventive treatment in pregnancy (IPTp) diminishes placental malaria (PM) and its subsequent malaria-associated morbidity." | 2.50 | Pregnancy-associated malaria and malaria in infants: an old problem with present consequences. ( Abellana, R; Cot, M; Moya-Alvarez, V, 2014) |
| "007) and dosage (p = 0." | 1.72 | Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi ( Achidi, EA; Amambua-Ngwa, A; Anchang-Kimbi, JK; Apinjoh, TO; Chi, HF; Dionne-Odom, J; Kwi, PN; Mayaba, JM; Moyeh, MN; Ntui, VN; Tangi, LN; Tita, ATN; Titanji, VPK; Toussi, CT, 2022) |
| "Chloroquine failure rate was high which was well above the WHO recommended cut off threshold for drug policy change (> 10%), Sulfadoxine- Pyrimethamine can be used in place of Chloroquine as the first line drug in uncomplicated P." | 1.42 | Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata. ( Basu, A; Guha, SK; Saha, S, 2015) |
| "Intermittent preventive treatment during pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) is protective against malaria but may also affect hematopoiesis and contribute to fetal anemia." | 1.38 | The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi. ( Chaluluka, E; Feng, G; Meshnick, SR; Molyneux, ME; Rogawski, ET; Rogerson, SJ, 2012) |
| " There was significant association between gravidity and SP dosage taken (Pearson χ2 = 18." | 1.37 | The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana. ( Browne, E; Lawson, B; Tutu, EO, 2011) |
| "Parasite recrudescences in 33 consecutive paired episodes during the same pregnancy were identified by msp1 and msp2 genotyping." | 1.35 | Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women. ( Alonso, PL; Aponte, JJ; Bardají, A; Cisteró, P; Mandomando, I; Mayor, A; Menéndez, C; Puyol, L; Sanz, S; Serra-Casas, E; Sigauque, B, 2009) |
| ") was tested alone, or in a double and triple combination with a fixed oral dose of 1." | 1.35 | Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model. ( Ishih, A; Kano, S; Kino, H; Muregi, FW, 2009) |
| "Falciparum Malaria is hyperendemic in southern Nigeria and chloroquine resistance is an increasing problem." | 1.33 | Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine. ( Göbels, K; Graupner, J; Grobusch, MP; Häussinger, D; Lund, A; Richter, J, 2005) |
| "Sulfadoxine-pyremethamine treatment alone cured 68." | 1.33 | The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis. ( A-Elbasit, IE; Alifrangis, M; Elbashir, MI; Giha, HA; Khalil, IF, 2006) |
| "falciparum malaria were initially treated with chloroquine (CQ)." | 1.32 | Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India. ( Barman, K; Dev, V; Phookan, S, 2003) |
| "This work shows that an early treatment of a malaria infection produced by a non-lethal parasite drives the immune response towards a loss of cross-protection to further infections, in particular with more virulent parasites." | 1.32 | Early treatment during a primary malaria infection modifies the development of cross immunity. ( Hernández-Clemente, FF; Legorreta-Herrera, M; Licona-Chávez, RN; Soto-Cruz, I; Ventura-Ayala, ML, 2004) |
| "Amodiaquine was 3." | 1.31 | In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar. ( Ariey, F; Duchemin, JB; Harisoa, JL; Mauclere, P; Pietra, V; Rabarijaona, LP; Raharimalala, LA; Rakotomanana, F; Ranaivo, L; Randrianarivelojosia, M; Robert, V, 2002) |
| " From September to December 1998, 598 children with uncomplicated malaria were treated; 135 received chloroquine (CQ) alone, 276 received pyrimethamine/sulfadoxine (Fansidar, PSD) alone, 113 received PSD with a single dose of artesunate (PSD + 1ART) and 74 received PSD combined with three doses of artesunate (PSD + 3ART)." | 1.31 | Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria. ( Coleman, R; Doherty, T; Jawara, M; Targett, G; von Seidlein, L; Walraven, G, 2001) |
| "falciparum malaria were treated with PS and monitored for 56 days." | 1.30 | Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali. ( Cortese, JF; Coulibaly, Y; Diakité, M; Diallo, M; Dicko, A; Diourté, Y; Djimdé, A; Doumbo, OK; Plowe, CV; Sagara, I, 1999) |
| "Chloroquine was prescribed at 25 mg/kg for 3 days in febrile patients with uncomplicated P." | 1.30 | [Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)]. ( Ali, I; Bendavid, C; Condomines, P; Crassard, N; Djermakoye, F; Faugère, B; Parola, P, 1999) |
| "Fever was the only clinical manifestation attributable to parasitemia and only when the parasite density was > or = 5000/microL." | 1.29 | Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design. ( Bales, JD; Beadle, C; Beier, JC; Chumo, DK; Hoffman, SL; McElroy, PD; Oloo, AJ; Onyango, FK; Oster, CN; Sherwood, JA, 1995) |
| "Oral pyrimethamine treatment (10 mg/kg for 4 days) in infected mice (5-10%) returned the altered levels of the above enzymes to almost normal 1 week after the cessation of drug treatment." | 1.29 | Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice. ( Agrawal, A; Pandey, VC; Puri, SK; Tripathi, LM, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.54) | 18.7374 |
| 1990's | 26 (14.05) | 18.2507 |
| 2000's | 95 (51.35) | 29.6817 |
| 2010's | 51 (27.57) | 24.3611 |
| 2020's | 12 (6.49) | 2.80 |
| Authors | Studies |
|---|---|
| Cohen, A | 1 |
| Suzanne, P | 1 |
| Lancelot, JC | 1 |
| Verhaeghe, P | 1 |
| Lesnard, A | 1 |
| Basmaciyan, L | 1 |
| Hutter, S | 1 |
| Laget, M | 1 |
| Dumètre, A | 1 |
| Paloque, L | 1 |
| Deharo, E | 1 |
| Crozet, MD | 1 |
| Rathelot, P | 1 |
| Dallemagne, P | 1 |
| Lorthiois, A | 1 |
| Sibley, CH | 1 |
| Vanelle, P | 1 |
| Valentin, A | 1 |
| Mazier, D | 1 |
| Rault, S | 1 |
| Azas, N | 1 |
| Joste, V | 1 |
| Guillochon, E | 1 |
| Clain, J | 1 |
| Coppée, R | 1 |
| Houzé, S | 1 |
| Apinjoh, TO | 1 |
| Ntui, VN | 1 |
| Chi, HF | 1 |
| Moyeh, MN | 1 |
| Toussi, CT | 1 |
| Mayaba, JM | 1 |
| Tangi, LN | 1 |
| Kwi, PN | 1 |
| Anchang-Kimbi, JK | 1 |
| Dionne-Odom, J | 1 |
| Tita, ATN | 1 |
| Achidi, EA | 2 |
| Amambua-Ngwa, A | 1 |
| Titanji, VPK | 1 |
| Crider, K | 1 |
| Williams, J | 1 |
| Qi, YP | 1 |
| Gutman, J | 2 |
| Yeung, L | 1 |
| Mai, C | 1 |
| Finkelstain, J | 1 |
| Mehta, S | 1 |
| Pons-Duran, C | 3 |
| Menéndez, C | 4 |
| Moraleda, C | 1 |
| Rogers, L | 1 |
| Daniels, K | 1 |
| Green, P | 1 |
| Hallamaa, L | 1 |
| Ashorn, P | 1 |
| Cheung, YB | 1 |
| Luntamo, M | 1 |
| Ashorn, U | 1 |
| Kulmala, T | 1 |
| Maleta, K | 1 |
| Mangani, C | 1 |
| Fan, YM | 1 |
| Pestehchian, N | 1 |
| Vafaei, MR | 1 |
| Nematolahy, P | 1 |
| Varshosaz, J | 1 |
| Yousefi, HA | 1 |
| Bide, VZ | 1 |
| Kalani, H | 1 |
| Moore, BR | 1 |
| Benjamin, JM | 1 |
| Tobe, R | 1 |
| Ome-Kaius, M | 1 |
| Yadi, G | 1 |
| Kasian, B | 1 |
| Kong, C | 1 |
| Robinson, LJ | 1 |
| Laman, M | 1 |
| Mueller, I | 1 |
| Rogerson, S | 1 |
| Davis, TME | 1 |
| Umemmuo, MU | 1 |
| Agboghoroma, CO | 1 |
| Iregbu, KC | 1 |
| Chaponda, EB | 1 |
| Mharakurwa, S | 1 |
| Michelo, C | 1 |
| Bruce, J | 2 |
| Chandramoha, D | 1 |
| Matthew Chico, R | 1 |
| Al Khaja, KAJ | 1 |
| Sequeira, RP | 1 |
| Agyeman, YN | 1 |
| Newton, S | 1 |
| Annor, RB | 1 |
| Owusu-Dabo, E | 1 |
| Andronescu, LR | 1 |
| Sharma, A | 1 |
| Peterson, I | 1 |
| Kachingwe, M | 1 |
| Kachepa, W | 1 |
| Liang, Y | 1 |
| Gutman, JR | 2 |
| Mathanga, DP | 2 |
| Chinkhumba, J | 1 |
| Laufer, MK | 3 |
| Esu, EB | 1 |
| Oringanje, C | 1 |
| Meremikwu, MM | 1 |
| Toukam, LL | 1 |
| Tatsinkou Fossi, B | 1 |
| Taiwe, GS | 1 |
| Bila, RB | 1 |
| Feugaing Sofeu, DD | 1 |
| Ivo, EP | 1 |
| Mohamed, AO | 1 |
| Abdel Hamid, MM | 1 |
| Mohamed, OS | 1 |
| Elkando, NS | 1 |
| Suliman, A | 1 |
| Adam, MA | 1 |
| Elnour, FAA | 1 |
| Malik, EM | 4 |
| Sandoval, E | 1 |
| Lafuente-Monasterio, MJ | 1 |
| Almela, MJ | 1 |
| Castañeda, P | 1 |
| Jiménez Díaz, MB | 1 |
| Martínez-Martínez, MS | 1 |
| Vidal, J | 1 |
| Angulo-Barturen, Í | 1 |
| Bamborough, P | 1 |
| Burrows, J | 1 |
| Cammack, N | 1 |
| Chaparro, MJ | 1 |
| Coterón, JM | 1 |
| de Cozar, C | 1 |
| Crespo, B | 1 |
| Díaz, B | 1 |
| Drewes, G | 1 |
| Fernández, E | 1 |
| Ferrer-Bazaga, S | 1 |
| Fraile, MT | 1 |
| Gamo, FJ | 1 |
| Ghidelli-Disse, S | 1 |
| Gómez, R | 1 |
| Haselden, J | 1 |
| Huss, S | 1 |
| León, ML | 1 |
| de Mercado, J | 1 |
| Macdonald, SJF | 1 |
| Martín Hernando, JI | 1 |
| Prats, S | 1 |
| Puente, M | 1 |
| Rodríguez, A | 1 |
| de la Rosa, JC | 1 |
| Rueda, L | 1 |
| Selenski, C | 1 |
| Willis, P | 1 |
| Wilson, DM | 1 |
| Witty, M | 1 |
| Calderón, F | 1 |
| González, R | 2 |
| Piqueras, M | 2 |
| Aponte, JJ | 3 |
| Ter Kuile, FO | 4 |
| Akinyotu, O | 2 |
| Bello, F | 2 |
| Abdus-Salam, R | 2 |
| Arowojolu, A | 2 |
| Esu, E | 2 |
| Berens-Riha, N | 1 |
| Pritsch, M | 1 |
| Nwachuku, N | 1 |
| Loescher, T | 1 |
| Meremikwu, M | 2 |
| Chandramohan, D | 5 |
| Dicko, A | 4 |
| Zongo, I | 2 |
| Sagara, I | 3 |
| Cairns, M | 2 |
| Kuepfer, I | 1 |
| Diarra, M | 1 |
| Barry, A | 2 |
| Tapily, A | 1 |
| Nikiema, F | 1 |
| Yerbanga, S | 1 |
| Coumare, S | 1 |
| Thera, I | 1 |
| Traore, A | 1 |
| Milligan, P | 5 |
| Tinto, H | 3 |
| Doumbo, O | 4 |
| Ouedraogo, JB | 3 |
| Greenwood, B | 9 |
| Adeoye, IA | 1 |
| Fagbamigbe, AF | 1 |
| Olaleye, A | 1 |
| Okusanya, BO | 1 |
| Oduwole, O | 1 |
| Shah, NK | 1 |
| Schapira, A | 1 |
| Juliano, JJ | 1 |
| Srivastava, B | 1 |
| MacDonald, PD | 1 |
| Poole, C | 1 |
| Anvikar, A | 1 |
| Meshnick, SR | 5 |
| Valecha, N | 1 |
| Mishra, N | 1 |
| Moussiliou, A | 1 |
| De Tove, YS | 1 |
| Doritchamou, J | 1 |
| Luty, AJ | 1 |
| Massougbodji, A | 1 |
| Alifrangis, M | 4 |
| Deloron, P | 1 |
| Ndam, NT | 1 |
| Kikueta, CM | 1 |
| Kambu, OK | 1 |
| Mbenza, AP | 1 |
| Mavinga, ST | 1 |
| Mbamu, BM | 1 |
| Cos, P | 1 |
| Maes, L | 1 |
| Apers, S | 1 |
| Pieters, L | 1 |
| Cimanga, RK | 1 |
| Sharma, L | 1 |
| Shukla, G | 1 |
| Gogtay, N | 1 |
| Kannan, S | 1 |
| Thatte, UM | 1 |
| Olliaro, PL | 3 |
| Sinclair, D | 2 |
| Valea, I | 1 |
| Drabo, MK | 1 |
| Huybregts, L | 1 |
| Henry, MC | 1 |
| Roberfroid, D | 1 |
| Guiguemde, RT | 2 |
| Kolsteren, P | 1 |
| D'Alessandro, U | 4 |
| Mosha, D | 1 |
| Chilongola, J | 1 |
| Ndeserua, R | 1 |
| Mwingira, F | 1 |
| Genton, B | 3 |
| Moya-Alvarez, V | 1 |
| Abellana, R | 1 |
| Cot, M | 1 |
| Cohee, LM | 1 |
| Kalilani-Phiri, L | 1 |
| Boudova, S | 1 |
| Joshi, S | 1 |
| Mukadam, R | 1 |
| Seydel, KB | 1 |
| Mawindo, P | 1 |
| Thesing, P | 1 |
| Kamiza, S | 1 |
| Makwakwa, K | 1 |
| Muehlenbachs, A | 2 |
| Taylor, TE | 2 |
| Mpogoro, FJ | 1 |
| Matovelo, D | 1 |
| Dosani, A | 1 |
| Ngallaba, S | 1 |
| Mugono, M | 1 |
| Mazigo, HD | 1 |
| Mwandama, D | 1 |
| Wiegand, RE | 1 |
| Abdallah, J | 1 |
| Iriemenam, NC | 1 |
| Shi, YP | 1 |
| Skarbinski, J | 2 |
| Marquart, L | 1 |
| Baker, M | 1 |
| O'Rourke, P | 1 |
| McCarthy, JS | 1 |
| Basu, A | 1 |
| Saha, S | 1 |
| Guha, SK | 1 |
| Awine, T | 2 |
| Belko, MM | 1 |
| Oduro, AR | 2 |
| Oyakhirome, S | 2 |
| Tagbor, H | 1 |
| Williams, JE | 1 |
| Kakuru, A | 1 |
| Jagannathan, P | 1 |
| Muhindo, MK | 1 |
| Natureeba, P | 1 |
| Awori, P | 1 |
| Nakalembe, M | 1 |
| Opira, B | 1 |
| Olwoch, P | 1 |
| Ategeka, J | 1 |
| Nayebare, P | 1 |
| Clark, TD | 2 |
| Feeney, ME | 1 |
| Charlebois, ED | 1 |
| Rizzuto, G | 1 |
| Havlir, DV | 1 |
| Kamya, MR | 2 |
| Dorsey, G | 4 |
| Bouyou-Akotet, MK | 1 |
| Mawili-Mboumba, DP | 1 |
| Kendjo, E | 1 |
| Moutandou Chiesa, S | 1 |
| Tshibola Mbuyi, ML | 1 |
| Tsoumbou-Bakana, G | 1 |
| Zong, J | 1 |
| Ambounda, N | 1 |
| Kombila, M | 1 |
| Mwangi, VI | 1 |
| Mumo, RM | 1 |
| Kiboi, DM | 1 |
| Omar, SA | 2 |
| Ng'ang'a, ZW | 1 |
| Ozwara, HS | 1 |
| Matangila, JR | 1 |
| Doua, JY | 1 |
| Mitashi, P | 1 |
| da Luz, RI | 1 |
| Lutumba, P | 1 |
| Van Geertruyden, JP | 1 |
| Adam, I | 3 |
| Elmardi, KA | 2 |
| Carmona-Fonseca, J | 2 |
| Arango, E | 1 |
| Blair, S | 1 |
| Clerk, CA | 1 |
| Affipunguh, PK | 1 |
| Mensah, N | 2 |
| Hodgson, A | 3 |
| Zikusooka, CM | 1 |
| McIntyre, D | 1 |
| Barnes, KI | 2 |
| Temperley, M | 1 |
| Mueller, DH | 1 |
| Njagi, JK | 1 |
| Akhwale, W | 1 |
| Clarke, SE | 1 |
| Jukes, MC | 1 |
| Estambale, BB | 1 |
| Brooker, S | 1 |
| Delenne, H | 1 |
| Cisse, M | 1 |
| Badiane, M | 1 |
| Olliaro, A | 1 |
| Vaillant, M | 1 |
| Brasseur, P | 1 |
| Okokon, JE | 1 |
| Nwafor, PA | 1 |
| Stepniewska, K | 1 |
| Price, RN | 1 |
| Sutherland, CJ | 2 |
| Drakeley, CJ | 2 |
| von Seidlein, L | 3 |
| Nosten, F | 1 |
| White, NJ | 2 |
| Mayor, A | 1 |
| Serra-Casas, E | 1 |
| Bardají, A | 1 |
| Sanz, S | 1 |
| Puyol, L | 1 |
| Cisteró, P | 1 |
| Sigauque, B | 1 |
| Mandomando, I | 1 |
| Alonso, PL | 1 |
| Gies, S | 2 |
| Coulibaly, SO | 1 |
| Ouattara, FT | 1 |
| Ogunfowokan, O | 1 |
| Dankyau, M | 1 |
| Madaki, AJ | 1 |
| Thacher, TD | 3 |
| Oesterholt, MJ | 1 |
| Sawa, P | 3 |
| Howitt, C | 1 |
| Gouagna, LC | 3 |
| Sauerwein, RW | 4 |
| Bousema, T | 4 |
| Msyamboza, KP | 1 |
| Savage, EJ | 1 |
| Kazembe, PN | 3 |
| Kalanda, G | 1 |
| Brabin, BJ | 3 |
| Muregi, FW | 1 |
| Kano, S | 1 |
| Kino, H | 1 |
| Ishih, A | 1 |
| Barger, B | 1 |
| Maiga, H | 2 |
| Traore, OB | 1 |
| Tekete, M | 1 |
| Tembine, I | 2 |
| Dara, A | 1 |
| Traore, ZI | 1 |
| Gantt, S | 1 |
| Doumbo, OK | 4 |
| Djimde, AA | 1 |
| Zani, B | 1 |
| Donegan, S | 1 |
| Olliaro, P | 2 |
| Garner, P | 1 |
| Hombhanje, FW | 1 |
| Linge, D | 1 |
| Saweri, A | 1 |
| Kuanch, C | 1 |
| Jones, R | 1 |
| Toraso, S | 1 |
| Geita, J | 1 |
| Masta, A | 1 |
| Kevau, I | 1 |
| Hiawalyer, G | 1 |
| Sapuri, M | 1 |
| Nakibuuka, V | 1 |
| Ndeezi, G | 1 |
| Nakiboneka, D | 1 |
| Ndugwa, CM | 1 |
| Tumwine, JK | 1 |
| Whegang, SY | 1 |
| Tahar, R | 1 |
| Foumane, VN | 1 |
| Soula, G | 1 |
| Gwét, H | 1 |
| Thalabard, JC | 1 |
| Basco, LK | 1 |
| Kinzer, MH | 1 |
| Chand, K | 1 |
| Basri, H | 1 |
| Lederman, ER | 1 |
| Susanti, AI | 1 |
| Elyazar, I | 1 |
| Taleo, G | 1 |
| Rogers, WO | 1 |
| Bangs, MJ | 2 |
| Maguire, JD | 1 |
| Okell, L | 2 |
| Shekalaghe, S | 1 |
| Griffin, JT | 1 |
| Omar, S | 2 |
| Sutherland, C | 1 |
| Sauerwein, R | 3 |
| Ghani, AC | 1 |
| Drakeley, C | 2 |
| Aziken, ME | 1 |
| Akubuo, KK | 1 |
| Gharoro, EP | 1 |
| Ouédraogo, A | 2 |
| Tiono, AB | 1 |
| Diarra, A | 2 |
| Nébié, IO | 1 |
| Konaté, AT | 1 |
| Sirima, SB | 2 |
| Kapito-Tembo, A | 1 |
| van Hensbroek, MB | 1 |
| Phiri, K | 1 |
| Fitzgerald, M | 1 |
| Mwapasa, V | 2 |
| Seboxa, T | 1 |
| Mao, P | 1 |
| Pinchouk, N | 1 |
| Anbessie, J | 1 |
| Alemu, H | 1 |
| Diro, E | 1 |
| Vanga-Bosson, HA | 1 |
| Coffie, PA | 1 |
| Kanhon, S | 1 |
| Sloan, C | 1 |
| Kouakou, F | 1 |
| Eholie, SP | 1 |
| Kone, M | 3 |
| Dabis, F | 1 |
| Menan, H | 1 |
| Ekouevi, DK | 1 |
| Tipsuwan, W | 1 |
| Srichairatanakool, S | 1 |
| Kamchonwongpaisan, S | 1 |
| Yuthavong, Y | 1 |
| Uthaipibull, C | 1 |
| Dicko, M | 1 |
| Diallo, AI | 1 |
| Dicko, Y | 1 |
| Dara, N | 1 |
| Sidibe, Y | 1 |
| Santara, G | 1 |
| Conaré, T | 1 |
| Cousens, S | 1 |
| Milligan, PJ | 1 |
| Diallo, DA | 1 |
| Shekalaghe, SA | 1 |
| van den Bosch, S | 1 |
| ter Braak, R | 1 |
| van den Bijllaardt, W | 1 |
| Mwanziva, C | 1 |
| Semvua, S | 1 |
| Masokoto, A | 1 |
| Mosha, F | 1 |
| Teelen, K | 1 |
| Hermsen, R | 1 |
| Gosling, R | 2 |
| Kiyingi, HS | 1 |
| Egwang, TG | 1 |
| Nannyonga, M | 1 |
| Taylor, SM | 2 |
| van Eijk, AM | 1 |
| Hand, CC | 1 |
| Mwandagalirwa, K | 1 |
| Messina, JP | 1 |
| Tshefu, AK | 1 |
| Atua, B | 1 |
| Emch, M | 1 |
| Muwonga, J | 1 |
| Tine, RC | 1 |
| Faye, B | 1 |
| Ndour, CT | 1 |
| Ndiaye, JL | 1 |
| Ndiaye, M | 1 |
| Bassene, C | 1 |
| Magnussen, P | 4 |
| Bygbjerg, IC | 2 |
| Sylla, K | 1 |
| Ndour, JD | 1 |
| Gaye, O | 1 |
| Tutu, EO | 1 |
| Lawson, B | 1 |
| Browne, E | 1 |
| Arango, EM | 1 |
| Upegui, YA | 1 |
| Umeh, UA | 1 |
| Obi, SN | 1 |
| Onah, HE | 1 |
| Ugwu, EO | 1 |
| Ajah, LO | 1 |
| Umeh, CR | 1 |
| Okafor, II | 1 |
| Antonia, AL | 1 |
| Chaluluka, E | 2 |
| Feng, G | 2 |
| Molyneux, ME | 2 |
| Rogerson, SJ | 2 |
| Khatib, RA | 2 |
| Njau, JD | 1 |
| Goodman, CA | 2 |
| Elling, BF | 2 |
| Kahigwa, E | 1 |
| Roberts, JM | 1 |
| MacArthur, JR | 1 |
| Kabanywanyi, AM | 1 |
| Smith, EE | 2 |
| Somi, MF | 1 |
| Lyimo, T | 1 |
| Mwita, A | 1 |
| Tanner, M | 1 |
| Mills, A | 1 |
| Mshinda, H | 3 |
| Bloland, PB | 5 |
| Abdulla, SM | 1 |
| Kachur, SP | 1 |
| Rutta, AS | 1 |
| Francis, F | 1 |
| Mmbando, BP | 1 |
| Ishengoma, DS | 1 |
| Sembuche, SH | 1 |
| Malecela, EK | 1 |
| Sadi, JY | 1 |
| Kamugisha, ML | 1 |
| Lemnge, MM | 1 |
| Rogawski, ET | 1 |
| Sangaré, D | 1 |
| Dolo, G | 1 |
| Guindo, A | 1 |
| Sissoko, M | 1 |
| Sogoba, M | 1 |
| Niambélé, MB | 1 |
| Yalcoué, D | 1 |
| Kaslow, DC | 1 |
| Klion, AD | 1 |
| Diallo, D | 1 |
| Miller, LH | 1 |
| Touré, Y | 1 |
| Méndez, F | 1 |
| Muñoz, A | 1 |
| Carrasquilla, G | 1 |
| Jurado, D | 1 |
| Arévalo-Herrera, M | 1 |
| Cortese, JF | 2 |
| Plowe, CV | 4 |
| Rodríguez, MC | 1 |
| Margos, G | 1 |
| Compton, H | 1 |
| Ku, M | 1 |
| Lanz, H | 1 |
| Rodríguez, MH | 1 |
| Sinden, RE | 2 |
| Terlouw, DJ | 1 |
| Aidoo, MA | 1 |
| Udhayakumar, V | 1 |
| Kolczak, MS | 1 |
| Oloo, AJ | 3 |
| Kager, PA | 2 |
| Lal, AA | 1 |
| Nahlen, BL | 1 |
| Kuile, FO | 1 |
| Randrianarivelojosia, M | 2 |
| Harisoa, JL | 1 |
| Rabarijaona, LP | 1 |
| Raharimalala, LA | 1 |
| Ranaivo, L | 1 |
| Pietra, V | 2 |
| Duchemin, JB | 1 |
| Rakotomanana, F | 1 |
| Robert, V | 2 |
| Mauclere, P | 1 |
| Ariey, F | 1 |
| Bousema, JT | 2 |
| Meutstege, AM | 2 |
| Okech, BE | 1 |
| Akim, NI | 1 |
| Githure, JI | 2 |
| Beier, JC | 3 |
| Sowunmi, A | 9 |
| Fateye, BA | 7 |
| JONES, SA | 1 |
| Ndyomugyenyi, R | 2 |
| Clarke, S | 1 |
| Dev, V | 1 |
| Phookan, S | 1 |
| Barman, K | 1 |
| Fehintola, FA | 6 |
| Adedeji, AA | 8 |
| Gbotosho, GO | 3 |
| Falade, CO | 3 |
| Tambo, E | 3 |
| Happi, TC | 3 |
| Oduola, AM | 4 |
| Müller, O | 1 |
| Traore, C | 1 |
| Kouyate, B | 1 |
| van den Broek, IV | 1 |
| van der Wardt, S | 1 |
| Talukder, L | 1 |
| Chakma, S | 1 |
| Brockman, A | 1 |
| Nair, S | 1 |
| Anderson, TC | 1 |
| Legorreta-Herrera, M | 1 |
| Ventura-Ayala, ML | 1 |
| Licona-Chávez, RN | 1 |
| Soto-Cruz, I | 1 |
| Hernández-Clemente, FF | 1 |
| Okech, BA | 1 |
| Akim, IN | 1 |
| Kengne, P | 1 |
| Zampan, H | 1 |
| Veas, F | 1 |
| Guiguemdé, TR | 1 |
| Randrianasolo, L | 1 |
| Randriamanantena, A | 1 |
| Ranarivelo, L | 1 |
| Ratsimbasoa, A | 1 |
| Domarle, O | 1 |
| Challis, K | 1 |
| Osman, NB | 1 |
| Cotiro, M | 1 |
| Nordahl, G | 1 |
| Dgedge, M | 2 |
| Bergström, S | 1 |
| Babalola, CP | 1 |
| Kayentao, K | 2 |
| Kodio, M | 2 |
| Newman, RD | 2 |
| Doumtabe, D | 1 |
| Ongoiba, A | 1 |
| Coulibaly, D | 2 |
| Keita, AS | 2 |
| Maiga, B | 2 |
| Mungai, M | 2 |
| Parise, ME | 2 |
| Anyorigiya, T | 1 |
| Ansah, P | 1 |
| Anto, F | 1 |
| Ansah, NA | 1 |
| Atuguba, F | 1 |
| Mumuni, G | 1 |
| Amankwa, J | 1 |
| Pitmang, SL | 1 |
| Madaki, JK | 2 |
| Egah, DZ | 1 |
| Fischer, PR | 1 |
| Nambei, WS | 1 |
| Gbagba, FE | 1 |
| Ndémanga, J | 1 |
| Doui-Doumgba, K | 1 |
| Diallo, TO | 1 |
| Ndadjimbaye, V | 1 |
| Flori, P | 1 |
| Perraut, R | 1 |
| Garraud, O | 1 |
| Graupner, J | 1 |
| Göbels, K | 1 |
| Grobusch, MP | 2 |
| Lund, A | 1 |
| Richter, J | 1 |
| Häussinger, D | 1 |
| A-Elbasit, IE | 2 |
| Idris, SM | 1 |
| Elbashir, MI | 2 |
| Mockenhaupt, FP | 1 |
| Teun Bousema, J | 1 |
| Eggelte, TA | 1 |
| Schreiber, J | 1 |
| Ehrhardt, S | 1 |
| Wassilew, N | 1 |
| Otchwemah, RN | 1 |
| Bienzle, U | 2 |
| Owusu-Agyei, S | 1 |
| Carneiro, I | 1 |
| Amponsa-Achiano, K | 1 |
| Jaffar, S | 1 |
| Baiden, R | 1 |
| Binka, F | 1 |
| Adjetey, TA | 2 |
| Affoumou, GB | 1 |
| Loukou, DD | 1 |
| Nebavi, NG | 2 |
| Barro-Kiki, P | 1 |
| Menan, EI | 2 |
| Yavo, W | 2 |
| Mugittu, K | 2 |
| Abdulla, S | 2 |
| Falk, N | 1 |
| Masanja, H | 1 |
| Felger, I | 1 |
| Beck, HP | 2 |
| Eggena, MP | 1 |
| Hopkins, H | 1 |
| Barugahare, B | 1 |
| Okello, M | 1 |
| Ssali, F | 1 |
| Mugyenyi, P | 1 |
| Rosenthal, PJ | 3 |
| Cao, H | 1 |
| Jongco, AM | 1 |
| Ting, LM | 1 |
| Thathy, V | 1 |
| Mota, MM | 1 |
| Kim, K | 1 |
| Schneider, P | 1 |
| Gouagna, L | 1 |
| Schallig, H | 1 |
| Patrick Kachur, S | 1 |
| Schulden, J | 1 |
| Kassala, H | 1 |
| Causer, LM | 1 |
| Mkikima, S | 1 |
| Zurovac, D | 1 |
| Midia, B | 1 |
| Ochola, SA | 1 |
| English, M | 1 |
| Snow, RW | 1 |
| Khalil, IF | 2 |
| Giha, HA | 1 |
| Mbaye, A | 2 |
| Richardson, K | 2 |
| Balajo, B | 2 |
| Dunyo, S | 2 |
| Shulman, C | 4 |
| Walraven, G | 4 |
| Mulenga, M | 3 |
| Malunga, P | 1 |
| Bennett, S | 2 |
| Thuma, P | 1 |
| Fielding, K | 2 |
| Cotte, AH | 1 |
| Konaté, A | 1 |
| Moran, AC | 1 |
| Asamoa, K | 1 |
| Bougouma, EC | 1 |
| Hugosson, E | 1 |
| Montgomery, SM | 1 |
| Premji, Z | 1 |
| Troye-Blomberg, M | 1 |
| Björkman, A | 1 |
| Fanello, CI | 1 |
| Karema, C | 1 |
| van Doren, W | 1 |
| Van Overmeir, C | 1 |
| Ngamije, D | 1 |
| Malunga, F | 1 |
| Thuma, PE | 1 |
| Alloueche, A | 2 |
| Greenwood, BM | 1 |
| Shah, SN | 1 |
| Obonyo, CO | 1 |
| Kain, KC | 1 |
| Slutsker, L | 1 |
| Hamel, MJ | 1 |
| Snyder, C | 1 |
| Chollet, J | 1 |
| Santo-Tomas, J | 1 |
| Scheurer, C | 1 |
| Wittlin, S | 1 |
| Kofoed, PE | 1 |
| Rodrigues, A | 1 |
| Aaby, P | 1 |
| Rombo, L | 1 |
| Ibrahium, AM | 1 |
| Kheir, MM | 1 |
| Osman, ME | 1 |
| Rouamba, N | 1 |
| Dokomajilar, C | 2 |
| Priotto, G | 1 |
| Guthmann, JP | 1 |
| Kiguli, J | 1 |
| Adjuik, M | 1 |
| Snounou, G | 1 |
| Taylor, WR | 1 |
| Staedke, S | 1 |
| Njama-Meya, D | 1 |
| Nzarubara, B | 1 |
| Maiteki-Sebuguzi, C | 1 |
| Mbonye, AK | 1 |
| Bygbjerg, I | 1 |
| Parise, M | 1 |
| Traoré, B | 2 |
| Tukur, IU | 1 |
| Sagay, AS | 1 |
| Yusuf, BO | 1 |
| Fadero, FF | 1 |
| Mokuolu, OA | 1 |
| Hamer, DH | 3 |
| Salako, LA | 1 |
| Happi, CT | 1 |
| Folarin, OA | 1 |
| van Oosterhout, JJ | 1 |
| Thesing, PC | 1 |
| Dzinjalamala, FK | 1 |
| Hsi, T | 1 |
| Beraho, L | 1 |
| Graham, SM | 1 |
| Gill, CJ | 2 |
| Macleod, WB | 2 |
| Mwanakasale, V | 2 |
| Chalwe, V | 2 |
| Mwananyanda, L | 2 |
| Champo, D | 2 |
| Mukwamataba, D | 2 |
| Chilengi, R | 2 |
| Thea, DM | 2 |
| Mubikayi, L | 1 |
| Mulele, CK | 1 |
| Lell, B | 2 |
| Schwarz, NG | 1 |
| Gabor, J | 1 |
| Dornemann, J | 1 |
| Potschke, M | 1 |
| Kiessling, GC | 1 |
| Necek, M | 1 |
| Langin, MU | 1 |
| Klein Klouwenberg, P | 1 |
| Klopfer, A | 1 |
| Naumann, B | 1 |
| Altun, H | 1 |
| Agnandji, ST | 1 |
| Goesch, J | 1 |
| Decker, M | 1 |
| Salazar, CL | 1 |
| Supan, C | 1 |
| Kombila, DU | 1 |
| Borchert, L | 1 |
| Koster, KB | 1 |
| Pongratz, P | 1 |
| Adegnika, AA | 1 |
| Glasenapp, Iv | 1 |
| Issifou, S | 1 |
| Kremsner, PG | 3 |
| Blanke, CH | 1 |
| Naisabha, GB | 1 |
| Balema, MB | 1 |
| Mbaruku, GM | 1 |
| Heide, L | 1 |
| Müller, MS | 1 |
| Little, F | 1 |
| Mabuza, A | 1 |
| Mngomezulu, N | 1 |
| Govere, J | 1 |
| Durrheim, D | 1 |
| Roper, C | 1 |
| Watkins, B | 1 |
| Beadle, C | 1 |
| McElroy, PD | 1 |
| Oster, CN | 1 |
| Onyango, FK | 1 |
| Chumo, DK | 1 |
| Bales, JD | 1 |
| Sherwood, JA | 1 |
| Hoffman, SL | 1 |
| Djimde, A | 2 |
| Bouare, M | 1 |
| Wellems, TE | 1 |
| Del Nero, L | 1 |
| Lamizana, L | 1 |
| Nebié, I | 1 |
| Hogh, B | 1 |
| Thompson, R | 1 |
| Hetzel, C | 1 |
| Fleck, SL | 1 |
| Kruse, NA | 1 |
| Jones, I | 1 |
| Barreto, J | 1 |
| Schultz, LJ | 1 |
| Steketee, RW | 1 |
| Macheso, A | 1 |
| Kazembe, P | 3 |
| Chitsulo, L | 1 |
| Wirima, JJ | 1 |
| Metzger, W | 1 |
| Mordmüller, B | 1 |
| Graninger, W | 1 |
| Agrawal, A | 1 |
| Tripathi, LM | 1 |
| Puri, SK | 2 |
| Pandey, VC | 1 |
| Nwanyanwu, OC | 1 |
| Ziba, C | 1 |
| Gamadzi, G | 1 |
| Gandwe, J | 1 |
| Redd, SC | 1 |
| Miédougé, M | 1 |
| Bessières, MH | 1 |
| Cassaing, S | 1 |
| Swierczynski, B | 1 |
| Séguéla, JP | 1 |
| Okoyeh, JN | 1 |
| Lege-Oguntoye, L | 1 |
| Ugbode, RO | 1 |
| Ogunrinde, GO | 1 |
| Verhoeff, FH | 2 |
| Masache, P | 1 |
| Kachale, B | 1 |
| Van der Kaay, HJ | 1 |
| Ménard, R | 1 |
| Janse, C | 1 |
| Puta, C | 1 |
| Manyando, C | 1 |
| Chimsuku, L | 1 |
| Russell, WB | 1 |
| Broadhead, RL | 1 |
| Collins, WE | 1 |
| Warren, M | 1 |
| Barat, LM | 2 |
| Himonga, B | 2 |
| Nkunika, S | 1 |
| Ettling, M | 1 |
| Ruebush, TK | 2 |
| Kapelwa, W | 1 |
| Shulman, CE | 1 |
| Dorman, EK | 1 |
| Cutts, F | 1 |
| Kawuondo, K | 1 |
| Bulmer, JN | 1 |
| Peshu, N | 1 |
| Marsh, K | 1 |
| Fryauff, DJ | 1 |
| Sumawinata, I | 1 |
| Richie, TL | 1 |
| Tjitra, E | 2 |
| Kadir, A | 1 |
| Ingkokusumo, G | 1 |
| Caraballo, A | 1 |
| Rodriguez-Acosta, A | 1 |
| Kocken, CH | 1 |
| van der Wel, A | 1 |
| Thomas, AW | 1 |
| Diourté, Y | 1 |
| Coulibaly, Y | 1 |
| Diallo, M | 1 |
| Diakité, M | 1 |
| Jelinek, T | 1 |
| Kilian, AH | 1 |
| Westermeier, A | 1 |
| Pröll, S | 1 |
| Kabagambe, G | 1 |
| Nothdurft, HD | 1 |
| von Sonnenburg, F | 1 |
| Löscher, T | 1 |
| Kun, JF | 1 |
| Klabunde, J | 1 |
| Luckner, D | 1 |
| Alpers, M | 1 |
| May, J | 1 |
| Meyer, C | 1 |
| Singh, N | 1 |
| Pinder, M | 1 |
| Bojang, K | 1 |
| Anyalebechi, C | 1 |
| Coleman, R | 2 |
| Ude, JI | 1 |
| Sadiq, A | 1 |
| Duraisingh, M | 1 |
| Warhurst, D | 1 |
| Targett, G | 2 |
| McAdam, K | 1 |
| Doherty, T | 2 |
| Wilairatana, P | 1 |
| Silachamroon, U | 1 |
| Krudsood, S | 1 |
| Singhasivanon, P | 1 |
| Treeprasertsuk, S | 1 |
| Bussaratid, V | 1 |
| Phumratanaprapin, W | 1 |
| Srivilirit, S | 1 |
| Looareesuwan, S | 1 |
| Parola, P | 1 |
| Ali, I | 1 |
| Djermakoye, F | 1 |
| Crassard, N | 1 |
| Bendavid, C | 1 |
| Faugère, B | 1 |
| Condomines, P | 1 |
| Babiker, HA | 1 |
| Abdel-Muhsin, AA | 1 |
| Hamad, A | 1 |
| Mackinnon, MJ | 1 |
| Hill, WG | 1 |
| Walliker, D | 1 |
| Awono-Ambene, HP | 1 |
| Le Hesran, JY | 1 |
| Trape, JF | 1 |
| Falade, AG | 2 |
| Akinyinka, OO | 1 |
| Gorissen, E | 1 |
| Ashruf, G | 1 |
| Lamboo, M | 1 |
| Bennebroek, J | 1 |
| Gikunda, S | 1 |
| Mbaruku, G | 1 |
| Sowunmi, CO | 1 |
| Sijuade, AO | 1 |
| Figueroa, MS | 1 |
| Bou, G | 1 |
| Marti-Belda, P | 1 |
| Lopez-Velez, R | 1 |
| Guerrero, A | 1 |
| Jawara, M | 1 |
| Suprianto, S | 1 |
| Currie, BJ | 1 |
| Morris, PS | 1 |
| Saunders, JR | 1 |
| Anstey, NM | 1 |
| Okafor, HU | 1 |
| Nwaiwu, O | 1 |
| Barro-Kiki, PC | 1 |
| Nigué, L | 1 |
| Konan, YJ | 1 |
| Tarimo, DS | 1 |
| Minjas, JN | 1 |
| Bustos, DG | 1 |
| Lazaro, JE | 1 |
| Gay, F | 1 |
| Pottier, A | 1 |
| Laracas, CJ | 1 |
| Diquet, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi[NCT03009526] | Phase 3 | 602 participants (Actual) | Interventional | 2017-01-17 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Cameroon[NCT06173206] | Phase 3 | 900 participants (Anticipated) | Interventional | 2024-03-15 | Not yet recruiting | ||
| A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients[NCT02524444] | Phase 1 | 142 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Comparison of IST Using Ultra-sensitive Malaria Rapid Diagnostic Test and Pyronaridine - Artesunate - PYRAMAX®) to Standard IPT Sulfadoxine-pyrimethamine to Prevent Malaria in Pregnant Women Living in Endemic Areas[NCT04783051] | Phase 3 | 250 participants (Actual) | Interventional | 2021-05-06 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise[NCT00121641] | Phase 3 | 1,035 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children[NCT02211729] | Phase 3 | 22,090 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi[NCT01120145] | 1,410 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects[NCT02223871] | Phase 1 | 8 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity[NCT05757167] | Phase 4 | 2,500 participants (Anticipated) | Interventional | 2023-11-06 | Recruiting | ||
| Operational Feasibility, Impact of Additional Screening Using Highly-sensitives RDTs Combined With High Coverage of IPTp on Placental Malaria and Low Birth Weight[NCT04147546] | Phase 3 | 340 participants (Actual) | Interventional | 2020-08-31 | Completed | ||
| Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)[NCT02163447] | Phase 3 | 300 participants (Actual) | Interventional | 2014-06-23 | Completed | ||
| [NCT01075945] | Phase 4 | 140 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial[NCT00146783] | Phase 2/Phase 3 | 3,642 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa[NCT02974348] | Phase 3 | 300 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi[NCT03376217] | 1,447 participants (Actual) | Interventional | 2017-12-01 | Completed | |||
| Determining the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04301531] | 5,861 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| Exploring the Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children in the Pakro Sub District of Ghana[NCT04167566] | 5,000 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Children With Sickle Cell Anaemia in Eastern and Southern Africa: a Double Blind Randomised Trial (CHEMCHA)[NCT04844099] | Phase 3 | 723 participants (Actual) | Interventional | 2021-04-09 | Completed | ||
| Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial[NCT00124267] | Phase 3 | 108 participants | Interventional | 2003-09-30 | Active, not recruiting | ||
| Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda[NCT01365598] | Phase 3 | 468 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children[NCT00738946] | 6,000 participants (Anticipated) | Interventional | 2008-08-31 | Completed | |||
| Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial[NCT01878357] | Phase 4 | 1,488 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine[NCT00509015] | 6,000 participants (Anticipated) | Interventional | 2008-02-29 | Completed | |||
| Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria[NCT00167739] | Phase 4 | 50 participants | Interventional | 2003-04-30 | Completed | ||
| Effect of Single-course Malaria Chemoprevention on Clearance of and Protection From Plasmodium Falciparum Infection in the Presence of Resistance-associated Genotypes in Zambia[NCT06166498] | Phase 3 | 600 participants (Anticipated) | Interventional | 2024-02-15 | Not yet recruiting | ||
| Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation[NCT00857077] | 2,485 participants (Actual) | Interventional | 2000-09-30 | Completed | |||
| Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy[NCT00123552] | Phase 3 | 601 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia[NCT00270530] | Phase 4 | 454 participants | Interventional | 2002-11-30 | Completed | ||
| A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health[NCT00167843] | Phase 4 | 1,189 participants | Interventional | 2002-12-31 | Completed | ||
| A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined[NCT03143218] | Phase 3 | 5,920 participants (Actual) | Interventional | 2017-04-17 | Completed | ||
| Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea[NCT01136850] | Phase 3 | 2,793 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria[NCT00214643] | Phase 3 | 160 participants | Interventional | 2005-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 9 |
| Saxagliptin 5 mg | 11 |
| Saxagliptin 10 mg | 10 |
| Placebo | 9 |
Hypoglycemic Events are based upon the Saxagliptin Predefined List of Events, which included hypoglycemia, blood glucose decreased, and hypoglycemic unconsciousness. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 2 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | years (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 49.09 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | kg/m^2 (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 31.73 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | kg (Mean) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 91.41 |
'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 1 |
| Saxagliptin 5 mg | 1 |
| Saxagliptin 10 mg | 0 |
| Placebo | 0 |
'Confirmed' = recorded on the hypoglycemia AE case report form page with a fingerstick glucose <= 50 mg/dL and associated symptoms (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) |
|---|---|
| Open-Label Treatment Cohort (Direct Enrollees) | 0 |
(NCT00121641)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Saxagliptin 2.5 mg | 35.0 |
| Saxagliptin 5 mg | 37.9 |
| Saxagliptin 10 mg | 41.1 |
| Placebo | 23.9 |
(NCT00121641)
Timeframe: Week 24
| Intervention | percentage of participants (Number) |
|---|---|
| Open Label Cohort (Direct Enrollees) | 14.1 |
To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | Percentage of glycosylated hemoglobins (Mean) | |
|---|---|---|
| Baseline Mean | Mean Change from Baseline | |
| Open Label Cohort (Direct Enrollees) | 10.70 | -1.87 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Adjusted Change from Baseline | |
| Placebo | 171.85 | 6.06 |
| Saxagliptin 10 mg | 176.51 | -16.75 |
| Saxagliptin 2.5 mg | 177.72 | -14.53 |
| Saxagliptin 5 mg | 171.31 | -8.67 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Open-Label Cohort (Direct Enrollees) | 241.08 | -33.42 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | |
|---|---|---|
| Baseline | Adjusted Change from Baseline | |
| Placebo | 46030 | -646.6 |
| Saxagliptin 10 mg | 44614 | -8084 |
| Saxagliptin 2.5 mg | 45030 | -6868 |
| Saxagliptin 5 mg | 45691 | -6896 |
(NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | mg*min/dL (Mean) | |
|---|---|---|
| Baseline | Change from Baseline | |
| Open Label Cohort (Direct Enrollees) | 60687 | -11078 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.02 | 0.00 | -0.00 | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | -0.01 | -0.00 | -0.00 | -0.01 | 0.01 | 0.00 | 0.02 | 0.02 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.01 |
| Saxagliptin 10 mg | 0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.01 | -0.00 | -0.01 | 0.00 | -0.01 | -0.01 | 0.00 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 | 0.00 | 0.01 | 0.01 |
| Saxagliptin 2.5 mg | 0.01 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 | 0.02 | 0.01 | 0.01 | 0.00 |
| Saxagliptin 5 mg | 0.02 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.01 | 0.00 | -0.00 | 0.00 | -0.01 | -0.00 | -0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.20 | -0.02 | -0.02 | -0.02 | -0.01 | 0.01 | -0.02 | -0.01 | -0.00 | 0.00 | -0.03 | -0.02 | -0.04 | -0.03 | -0.02 | -0.01 | -0.02 | -0.03 | -0.02 | -0.01 | -0.00 | -0.01 | 0.01 | 0.03 | 0.06 | 0.07 | 0.05 | 0.06 |
| Saxagliptin 10 mg | 0.20 | -0.02 | -0.01 | -0.02 | -0.02 | -0.02 | -0.01 | -0.01 | -0.03 | -0.03 | -0.04 | -0.04 | -0.03 | -0.02 | -0.04 | -0.02 | -0.00 | -0.02 | -0.02 | 0.02 | -0.01 | -0.03 | -0.00 | -0.01 | 0.01 | -0.00 | 0.00 | 0.03 |
| Saxagliptin 2.5 mg | 0.18 | -0.01 | -0.02 | 0.01 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.02 | -0.00 | -0.02 | -0.03 | -0.03 | -0.03 | -0.00 | -0.03 | -0.03 | 0.02 | -0.00 | -0.02 | -0.01 | 0.00 | -0.02 | -0.02 | -0.01 | 0.00 |
| Saxagliptin 5 mg | 0.20 | 0.01 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.03 | -0.03 | -0.03 | -0.03 | -0.01 | -0.01 | 0.00 | -0.04 | -0.02 | 0.01 | 0.07 | 0.02 | -0.00 | -0.00 | -0.02 | -0.01 | -0.01 | -0.00 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=39, 48, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 2.22 | -0.13 | -0.04 | -0.09 | -0.00 | 0.05 | -0.02 | 0.06 | 0.01 | 0.08 | -0.11 | 0.09 | -0.01 | -0.03 | -0.08 | -0.03 | -0.16 | -0.20 | -0.23 | -0.16 | -0.10 | -0.06 | 0.00 | -0.14 | -0.16 | -0.05 | 0.01 | -0.08 |
| Saxagliptin 10 mg | 2.14 | -0.11 | -0.18 | -0.23 | -0.20 | -0.10 | -0.16 | -0.01 | -0.11 | 0.01 | -0.10 | -0.07 | -0.13 | -0.09 | -0.17 | -0.25 | -0.19 | -0.18 | -0.19 | -0.23 | -0.21 | -0.16 | -0.10 | -0.23 | -0.11 | -0.06 | -0.04 | -0.05 |
| Saxagliptin 2.5 mg | 2.16 | -0.04 | -0.03 | -0.04 | -0.07 | 0.07 | -0.06 | 0.20 | 0.03 | 0.11 | 0.08 | 0.16 | -0.00 | 0.08 | 0.05 | -0.06 | -0.06 | -0.10 | -0.12 | -0.17 | -0.15 | -0.12 | -0.13 | -0.23 | -0.23 | -0.15 | -0.06 | -0.17 |
| Saxagliptin 5 mg | 2.21 | -0.10 | -0.12 | -0.09 | -0.11 | 0.02 | -0.12 | 0.08 | 0.01 | 0.13 | -0.02 | 0.13 | -0.07 | -0.00 | 0.02 | -0.09 | -0.10 | -0.09 | -0.02 | -0.07 | -0.00 | -0.00 | -0.03 | 0.04 | -0.13 | -0.22 | -0.09 | -0.14 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 0.32 | -0.01 | 0.01 | 0.02 | -0.02 | 0.03 | 0.01 | 0.04 | 0.01 | 0.04 | 0.01 | 0.05 | 0.03 | 0.03 | 0.00 | 0.06 | 0.07 | 0.05 | 0.05 | 0.07 | 0.13 | 0.07 | 0.10 | 0.08 | 0.11 | 0.11 | 0.13 | 0.09 |
| Saxagliptin 10 mg | 0.32 | -0.05 | -0.01 | -0.01 | -0.01 | 0.04 | 0.00 | 0.03 | 0.04 | 0.06 | 0.04 | 0.06 | 0.03 | 0.04 | 0.04 | 0.05 | 0.07 | 0.06 | 0.08 | 0.09 | 0.06 | 0.07 | 0.10 | 0.06 | 0.10 | 0.11 | 0.11 | 0.13 |
| Saxagliptin 2.5 mg | 0.31 | 0.01 | 0.05 | 0.05 | 0.03 | 0.08 | 0.05 | 0.09 | 0.06 | 0.06 | 0.04 | 0.08 | 0.04 | 0.05 | 0.06 | 0.07 | 0.08 | 0.12 | 0.11 | 0.14 | 0.12 | 0.12 | 0.08 | 0.10 | 0.07 | 0.08 | 0.09 | 0.05 |
| Saxagliptin 5 mg | 0.34 | 0.01 | 0.00 | -0.01 | 0.03 | 0.04 | 0.00 | 0.06 | 0.04 | 0.05 | 0.02 | 0.05 | 0.01 | 0.03 | 0.02 | 0.03 | 0.05 | 0.04 | 0.03 | 0.04 | 0.05 | 0.04 | 0.02 | 0.05 | 0.04 | 0.04 | 0.04 | 0.05 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=91, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 88, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 77, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 75, 65) | Change from BL at Week 24 (n=83, 81, 78, 74) | Change from BL at Week 30 (n=76, 78, 79, 67) | Change from BL at Week 37 (n=74, 72, 70, 60) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 38, 34, 28) | Change from BL at Week 154 (n=26, 33, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 25, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 4.01 | -0.07 | 0.23 | 0.17 | 0.19 | 0.45 | 0.30 | 0.46 | 0.18 | 0.21 | 0.15 | 0.32 | -0.03 | 0.00 | 0.20 | 0.27 | 0.16 | -0.01 | 0.01 | 0.01 | 0.42 | 0.22 | 0.40 | 0.41 | 0.33 | 0.51 | -0.01 | 0.31 |
| Saxagliptin 10 mg | 4.16 | 0.00 | 0.05 | 0.04 | 0.03 | 0.17 | 0.18 | 0.17 | 0.16 | 0.32 | 0.07 | 0.44 | 0.16 | 0.32 | 0.24 | 0.19 | 0.08 | 0.08 | 0.05 | 0.24 | 0.29 | 0.56 | 0.45 | 0.47 | 0.27 | 0.55 | 0.51 | 0.90 |
| Saxagliptin 2.5 mg | 4.00 | -0.06 | 0.09 | 0.01 | 0.02 | 0.18 | 0.01 | 0.07 | 0.17 | 0.23 | 0.19 | 0.44 | 0.09 | 0.04 | 0.13 | 0.03 | 0.11 | 0.05 | 0.58 | 0.19 | 0.28 | 0.61 | 0.41 | 0.25 | -0.04 | 0.23 | 0.34 | 0.15 |
| Saxagliptin 5 mg | 3.98 | 0.11 | 0.16 | 0.19 | 0.27 | 0.48 | 0.21 | 0.64 | 0.49 | 0.67 | 0.32 | 0.58 | 0.57 | 0.29 | 0.42 | 0.40 | 0.25 | 0.33 | 0.18 | 0.43 | 0.81 | 0.59 | 0.80 | 0.39 | 0.56 | 0.50 | 0.08 | 0.63 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | percentage red blood cells (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87) | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90. 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 42.8 | -0.4 | 0.3 | 0.3 | 0.5 | 0.5 | 0.7 | 0.2 | 0.3 | 0.4 | 0.2 | 0.5 | 0.5 | 0.4 | -0.4 | 0.2 | 0.7 | 0.8 | 0.4 | -0.7 | 0.2 | -0.1 | -0.2 | -0.3 | -0.4 | -0.5 | -0.0 | -0.5 |
| Saxagliptin 10 mg | 42.7 | -0.7 | -0.1 | 0.0 | 0.2 | -0.2 | 0.6 | 0.2 | 0.6 | 0.3 | 0.1 | -0.3 | -0.1 | 0.2 | 0.4 | 0.1 | 0.6 | 0.7 | 1.2 | -0.0 | 0.2 | 0.0 | 0.2 | -1.0 | 0.2 | 1.0 | 0.5 | 0.2 |
| Saxagliptin 2.5 mg | 42.5 | -0.4 | -0.2 | 0.1 | 0.5 | 0.6 | 0.6 | 0.6 | 0.5 | 0.2 | 0.7 | 0.3 | 0.0 | 0.5 | 0.0 | 0.1 | 0.3 | 0.7 | 0.9 | -0.2 | -0.0 | 0.2 | -0.1 | -0.8 | -0.1 | 1.1 | 0.6 | -0.4 |
| Saxagliptin 5 mg | 42.8 | -0.2 | -0.2 | 0.3 | 0.4 | -0.0 | 0.4 | 0.6 | 0.7 | 0.4 | 0.4 | 0.2 | 0.2 | -0.1 | -0.1 | 0.3 | 0.1 | 0.5 | 0.9 | 0.5 | 0.6 | 0.3 | -0.1 | -0.8 | 0.2 | 0.6 | 1.1 | 0.2 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | g/dL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87) | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 14.50 | -0.09 | 0.10 | 0.04 | 0.09 | 0.04 | 0.16 | -0.03 | 0.04 | -0.03 | -0.19 | -0.18 | -0.14 | -0.18 | -0.33 | -0.01 | 0.08 | -0.10 | -0.10 | -0.29 | -0.19 | -0.33 | -0.36 | -0.25 | -0.24 | -0.61 | -0.39 | -0.32 |
| Saxagliptin 10 mg | 14.47 | -0.22 | -0.09 | -0.07 | -0.02 | -0.13 | -0.07 | -0.12 | 0.00 | -0.07 | -0.25 | -0.36 | -0.32 | -0.19 | -0.06 | -0.02 | 0.07 | -0.07 | -0.04 | -0.07 | -0.18 | -0.25 | -0.15 | -0.24 | -0.03 | -0.08 | -0.16 | 0.10 |
| Saxagliptin 2.5 mg | 14.49 | -0.21 | -0.16 | -0.12 | -0.00 | 0.01 | -0.04 | -0.09 | -0.10 | -0.26 | -0.16 | -0.35 | -0.37 | -0.25 | -0.31 | -0.17 | -0.18 | -0.27 | -0.18 | -0.32 | -0.41 | -0.38 | -0.40 | -0.45 | -0.51 | -0.38 | -0.45 | -0.51 |
| Saxagliptin 5 mg | 14.45 | -0.13 | -0.15 | -0.00 | 0.04 | -0.20 | -0.07 | -0.05 | 0.01 | -0.10 | -0.14 | -0.23 | -0.25 | -0.29 | -0.22 | 0.06 | -0.11 | -0.19 | -0.09 | -0.00 | -0.07 | -0.17 | -0.35 | -0.37 | -0.05 | -0.08 | -0.03 | -0.07 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^9 c/L (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=101, 106, 96, 94) | Change from BL at Week 2 (n=92, 96, 85, 82) | Change from BL at Week 4 (n=88, 97, 90, 90) | Change from BL at Week 6 (n=88, 93, 84, 81) | Change from BL at Week 8 (n=86, 85, 86, 77) | Change from BL at Week 10 (n=68, 75, 67, 62) | Change from BL at Week 12 (n=83, 84, 85, 82) | Change from BL at Week 14 (n=72, 79, 77, 74) | Change from BL at Week 16 (n=86, 88, 81, 69) | Change from BL at Week 18 (n=77, 71, 79, 70) | Change from BL at Week 20 (n=78, 78, 72, 70) | Change from BL at Week 22 (n=74, 72, 73, 62) | Change from BL at Week 24 (n=80, 76, 73, 72) | Change from BL at Week 30 (n=73, 74, 74, 67) | Change from BL at Week 37 (n=70, 68, 66, 59) | Change from BL at Week 50 (n=66, 67, 66, 59) | Change from BL at Week 63 (n=59, 64, 65, 54) | Change from BL at Week 76 (n=50, 58, 61, 49) | Change from BL at Week 89 (n=47, 56, 54, 42) | Change from BL at Week 102 (n=39, 47, 49, 39) | Change from BL at Week 115 (n=33, 41, 41, 34) | Change from BL at Week 128 (n=30, 38, 39, 30) | Change from BL at Week 141 (n=27, 39, 33, 27) | Change from BL at Week 154 (n=25, 35, 31, 23) | Change from BL at Week 167 (n=22, 32, 28, 26) | Change from BL at Week 180 (n=20, 27, 27, 25) | Change from BL at Week 193 (n=17, 25, 25, 22) | Change from BL at Week 206 (n=15, 21, 23, 21) | |
| Placebo | 259.8 | 9.5 | 11.3 | 9.5 | 4.0 | 7.1 | 4.0 | 5.2 | 3.2 | 5.8 | -1.3 | 5.0 | -3.0 | 4.5 | 0.1 | 6.6 | 10.2 | 1.2 | 2.7 | 9.7 | 9.2 | 2.6 | -1.3 | 8.8 | 4.3 | 4.0 | -12.0 | -6.1 |
| Saxagliptin 10 mg | 261.6 | 2.2 | 5.6 | -0.2 | -4.3 | -4.4 | -4.8 | -3.7 | -6.0 | -2.7 | -8.3 | -5.4 | -15.5 | -9.9 | -15.6 | -11.5 | -6.3 | -6.0 | -6.7 | -4.8 | -12.0 | -2.6 | -0.3 | -2.9 | -14.6 | -17.3 | -13.4 | 6.2 |
| Saxagliptin 2.5 mg | 251.1 | 1.8 | 11.2 | 4.3 | 0.4 | -0.8 | -6.3 | 1.2 | -2.3 | -1.1 | -1.9 | 0.3 | -7.1 | -2.0 | -14.3 | -2.5 | -3.1 | -2.0 | 3.5 | 3.2 | 5.0 | 3.8 | -1.1 | 5.0 | -18.0 | -11.1 | -13.6 | -2.6 |
| Saxagliptin 5 mg | 253.1 | 4.4 | 8.6 | 4.3 | 1.0 | 3.0 | -1.3 | 3.2 | 1.1 | 2.0 | -4.8 | -2.5 | -6.0 | -3.3 | -8.1 | -5.6 | -3.4 | -1.5 | 1.9 | -2.3 | -8.8 | -2.1 | -4.6 | 5.8 | -0.1 | -24.0 | -13.4 | -18.7 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^6 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95,100, 93, 87 | Change from BL at Week 4 (n=92, 99, 91, 91) | Change from BL at Week 6 (n=91, 96, 87, 82) | Change from BL at Week 8 (n=92, 90, 91, 79) | Change from BL at Week 10 (n=70, 76, 69, 63) | Change from BL at Week 12 (n=85, 88, 87, 82) | Change from BL at Week 14 (n=76, 80, 81, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 80, 78, 72) | Change from BL at Week 22 (n=78, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=75, 73, 70, 62) | Change from BL at Week 50 (n=67, 71, 71, 61) | Change from BL at Week 63 (n=61, 66, 67, 55) | Change from BL at Week 76 (n=51, 59, 63, 49) | Change from BL at Week 89 (n=49, 58, 56, 42) | Change from BL at Week 102 (n=40, 49, 51, 40) | Change from BL at Week 115 (n=34, 43, 43, 35) | Change from BL at Week 128 (n=30, 40, 40, 30) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 35, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 26) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 24, 21) | |
| Placebo | 4.82 | -0.05 | 0.04 | 0.02 | 0.05 | 0.07 | 0.08 | 0.04 | 0.06 | 0.04 | -0.01 | -0.01 | -0.01 | -0.03 | -0.09 | 0.01 | 0.05 | -0.03 | -0.07 | -0.13 | -0.06 | -0.10 | -0.11 | -0.09 | -0.10 | -0.17 | -0.10 | -0.08 |
| Saxagliptin 10 mg | 4.82 | -0.08 | -0.02 | 0.00 | 0.03 | -0.02 | 0.07 | 0.04 | 0.08 | 0.05 | 0.01 | -0.05 | -0.03 | -0.01 | 0.04 | 0.02 | 0.08 | 0.00 | -0.01 | -0.03 | -0.02 | -0.04 | -0.02 | -0.08 | -0.01 | -0.01 | -0.02 | 0.06 |
| Saxagliptin 2.5 mg | 4.80 | -0.06 | -0.01 | 0.00 | 0.05 | 0.05 | 0.05 | 0.05 | 0.06 | 0.01 | 0.03 | -0.01 | -0.04 | 0.00 | -0.04 | -0.02 | 0.00 | -0.07 | -0.04 | -0.10 | -0.04 | -0.05 | -0.10 | -0.13 | -0.11 | -0.05 | -0.05 | -0.03 |
| Saxagliptin 5 mg | 4.80 | -0.04 | -0.04 | 0.02 | 0.03 | -0.03 | 0.03 | 0.03 | 0.08 | 0.04 | 0.02 | -0.01 | -0.04 | -0.07 | -0.04 | 0.04 | -0.01 | -0.07 | -0.06 | -0.03 | -0.01 | -0.07 | -0.13 | -0.13 | -0.04 | -0.08 | -0.06 | -0.06 |
(NCT00121641)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | x 10^3 c/µL (Mean) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (BL) (Week 0) (n=102, 106, 98, 94) | Change from BL at Week 2 (n=95, 99, 92, 86) | Change from BL at Week 4 (n=92, 99, 90, 90) | Change from BL at Week 6 (n=89, 95, 87, 82) | Change from BL at Week 8 (n=91, 89, 90, 79) | Change from BL at Week 10 (n=68, 76, 69, 63) | Change from BL at Week 12 (n=83, 88, 87, 82) | Change from BL at Week 14 (n=76, 78, 80, 75) | Change from BL at Week 16 (n=90, 91, 83, 71) | Change from BL at Week 18 (n=78, 75, 82, 71) | Change from BL at Week 20 (n=83, 79, 78, 72) | Change from BL at Week 22 (n=77, 74, 76, 65) | Change from BL at Week 24 (n=83, 82, 78, 74) | Change from BL at Week 30 (n=77, 78, 79, 67) | Change from BL at Week 37 (n=74, 73, 70, 62) | Change from BL at Week 50 (n=67, 69, 71, 61) | Change from BL at Week 63 (n=60, 66, 67, 55) | Change from BL at Week 76 (n=51, 58, 63, 49) | Change from BL at Week 89 (n=48, 58, 56, 42) | Change from BL at Week 102 (n=39, 47, 51, 40) | Change from BL at Week 115 (n=34, 43, 42, 34) | Change from BL at Week 128 (n=30, 40, 40, 29) | Change from BL at Week 141 (n=28, 39, 34, 28) | Change from BL at Week 154 (n=26, 34, 31, 24) | Change from BL at Week 167 (n=24, 33, 30, 25) | Change from BL at Week 180 (n=21, 28, 28, 26) | Change from BL at Week 193 (n=19, 26, 26, 23) | Change from BL at Week 206 (n=17, 22, 23, 21) | |
| Placebo | 6.79 | -0.23 | 0.17 | 0.09 | 0.16 | 0.53 | 0.26 | 0.56 | 0.19 | 0.32 | 0.02 | 0.45 | -0.06 | -0.03 | 0.14 | 0.29 | 0.06 | -0.20 | -0.18 | -0.09 | 0.44 | 0.22 | 0.51 | 0.38 | 0.35 | 0.65 | 0.19 | 0.38 |
| Saxagliptin 10 mg | 6.82 | -0.14 | -0.16 | -0.18 | -0.17 | 0.12 | 0.05 | 0.22 | 0.04 | 0.42 | 0.01 | 0.44 | 0.08 | 0.28 | 0.12 | -0.03 | -0.04 | -0.07 | -0.10 | 0.10 | 0.11 | 0.44 | 0.44 | 0.30 | 0.27 | 0.59 | 0.60 | 1.01 |
| Saxagliptin 2.5 mg | 6.71 | -0.11 | 0.06 | 0.01 | -0.02 | 0.32 | -0.00 | 0.33 | 0.24 | 0.37 | 0.29 | 0.66 | 0.10 | 0.15 | 0.21 | 0.01 | 0.12 | 0.03 | 0.51 | 0.16 | 0.24 | 0.58 | 0.35 | 0.12 | -0.22 | 0.13 | 0.34 | 0.01 |
| Saxagliptin 5 mg | 6.75 | 0.05 | 0.05 | 0.10 | 0.18 | 0.55 | 0.09 | 0.71 | 0.54 | 0.82 | 0.29 | 0.72 | 0.47 | 0.33 | 0.42 | 0.33 | 0.20 | 0.23 | 0.17 | 0.44 | 0.93 | 0.66 | 0.78 | 0.44 | 0.44 | 0.30 | 0.02 | 0.55 |
This cohort represents a different population (screening A1C > 10.0% and ≤ 12.0%) than the double-blind cohort, and was presented separately in the study report. (NCT00121641)
Timeframe: Baseline
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age <65 years | Age >=65 years | Age >=75 years | Gender, Male | Gender, Female | Age =<50 years, females only | Age >50 years, females only | Race, White | Race, Black/African American | Race, Asian | Race, Other | Ethnicity, Hispanic/Latino | Ethnicity, Not Hispanic/Latino | Ethnicity, Not Reported | Body Mass Index <30% | Body Mass Index >=30% | |
| Open-Label Treatment Cohort (Direct Enrollees) | 64 | 2 | 0 | 32 | 34 | 19 | 15 | 61 | 3 | 1 | 1 | 13 | 37 | 16 | 22 | 44 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | mmHg (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 50) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 66, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=61, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 51, 51, 42) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | -1.5 | -1.8 | -1.9 | -2.4 | -3.4 | -1.8 | -2.7 | -2.1 | -2.1 | -2.2 | -1.7 | -3.4 | -2.8 | -2.0 | -0.6 | -0.5 | -0.3 | -0.1 | -1.2 | -1.0 | 1.0 | 1.3 | 1.3 | -1.1 | -0.8 | -0.2 | -0.2 |
| Saxagliptin 10 mg | -0.5 | 0.3 | -0.8 | -0.7 | -1.3 | -0.7 | -2.4 | -0.1 | -1.9 | -1.9 | -2.5 | -2.3 | -0.3 | -0.6 | -0.3 | -0.0 | 0.1 | -1.6 | -0.4 | -1.1 | 1.1 | 1.1 | 2.5 | 2.4 | 0.5 | 0.5 | 1.9 |
| Saxagliptin 2.5 mg | -0.0 | -1.4 | -1.5 | -1.4 | -0.8 | -1.3 | -2.5 | -1.5 | -2.3 | -2.2 | -3.0 | -1.5 | -1.4 | -0.4 | -1.7 | -0.1 | -1.6 | 0.4 | -1.1 | -0.9 | -1.8 | 0.9 | 1.2 | 0.8 | 1.4 | 0.8 | 0.3 |
| Saxagliptin 5 mg | -1.2 | -1.1 | -0.9 | -0.9 | -1.1 | -2.0 | -2.4 | -0.5 | -1.6 | -1.8 | -2.0 | -1.7 | -2.2 | -1.7 | 0.3 | -0.4 | -2.0 | -2.1 | -2.0 | -2.7 | -3.7 | -2.0 | -0.8 | 0.3 | -2.0 | -1.6 | -0.6 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | mmHg (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=24) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=35) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=44) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -3.7 | -1.7 | -2.8 | -2.0 | -1.0 | -3.7 | -4.5 | -2.8 | -3.3 | -2.1 | -2.8 | -3.4 | -3.8 | -2.0 | -1.3 | -0.9 | -1.0 | -2.6 | 1.0 | -4.1 | -3.7 | -6.0 | -0.5 | -2.5 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | beats per minute (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 49) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 65, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=62, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 51, 51, 42) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | 0.3 | -0.1 | 1.4 | -0.2 | 0.1 | 0.8 | 1.9 | -0.1 | 2.6 | 0.8 | 1.5 | -0.4 | -1.2 | -0.9 | -0.2 | 0.6 | 0.2 | -0.3 | -0.0 | 0.8 | 1.7 | 0.9 | -0.6 | 0.5 | -1.2 | 1.1 | -0.8 |
| Saxagliptin 10 mg | 0.2 | 0.7 | -0.6 | 0.2 | -1.0 | 0.5 | 0.6 | -0.1 | 1.5 | 1.3 | 0.9 | -0.7 | -0.7 | 0.5 | -0.2 | 0.9 | 0.4 | -0.9 | -0.1 | 1.0 | -0.7 | -0.6 | -1.3 | -2.1 | -2.0 | -2.4 | 0.0 |
| Saxagliptin 2.5 mg | -0.1 | 0.2 | -1.5 | -0.5 | -0.2 | 0.3 | 0.1 | -0.8 | -0.0 | 1.3 | 0.1 | -0.3 | -0.1 | -0.4 | -0.1 | -0.4 | -0.3 | -0.5 | -2.8 | -3.2 | -2.1 | -2.8 | -2.0 | -5.1 | -3.1 | -4.6 | -5.3 |
| Saxagliptin 5 mg | -0.5 | -1.1 | -0.6 | -0.9 | -1.5 | -1.2 | -0.5 | -1.5 | -0.8 | -1.5 | -0.3 | 0.1 | -1.2 | -1.4 | -0.7 | -2.5 | -3.3 | -1.5 | -1.5 | -2.3 | -4.5 | -3.5 | -2.6 | -0.8 | -5.3 | -4.2 | -2.6 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | beats per minute (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=23) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=34) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=43) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -0.8 | -0.4 | -0.3 | -0.7 | -1.8 | -3.0 | -2.0 | -0.7 | -2.0 | 1.6 | -0.4 | -0.4 | 0.6 | -1.6 | -2.9 | -3.0 | -0.4 | -1.3 | -0.3 | 1.7 | -1.6 | -3.4 | -1.5 | -1.9 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206
| Intervention | mmHg (Mean) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=96, 100, 94, 89) | Change from BL at Week 4 (n=96, 100, 92, 91) | Change from BL at Week 6 (n=91, 98, 88, 84) | Change from BL at Week 8 (n=94, 91, 91, 80) | Change from BL at Week 10 (n=51, 66, 51, 50) | Change from BL at Week 12 (n=82, 83, 87, 79) | Change from BL at Week 14 (n=65, 72, 66, 62) | Change from BL at Week 16 (n=87, 87, 81, 72) | Change from BL at Week 18 (n=73, 69, 76, 66) | Change from BL at Week 20 (n=84, 80, 76, 73) | Change from BL at Week 22 (n=78, 73, 76, 64) | Change from BL at Week 24 (n=84, 83, 77, 75) | Change from BL at Week 30 (n=79, 78, 79, 66) | Change from BL at Week 37 (n=77, 74, 71, 66) | Change from BL at Week 50 (n=70, 73, 73, 62) | Change from BL at Week 63 (n=62, 66, 69, 56) | Change from BL at Week 76 (n=53, 59, 64, 50) | Change from BL at Week 89 (n=49, 58, 56, 44) | Change from BL at Week 102 (n=42, 47, 50, 40) | Change from BL at Week 115 (n=34, 43, 43, 37) | Change from BL at Week 128 (n=31, 40, 41, 31) | Change from BL at Week 141 (n=29, 40, 35, 29) | Change from BL at Week 154 (n=27, 36, 33, 27) | Change from BL at Week 167 (n=24, 33, 30, 27) | Change from BL at Week 180 (n=21, 28, 28, 27) | Change from BL at Week 193 (n=19, 26, 27, 24) | Change from BL at Week 206 (n=17, 24, 24, 23) | |
| Placebo | -3.1 | -4.3 | -4.5 | -5.5 | -6.1 | -3.2 | -1.9 | -2.1 | -4.7 | -4.9 | -3.9 | -6.3 | -5.4 | -3.6 | -0.4 | -2.4 | -0.9 | -2.2 | -1.0 | 0.9 | 1.1 | -1.4 | 2.3 | -0.6 | -0.8 | -2.6 | 0.7 |
| Saxagliptin 10 mg | -2.3 | -2.3 | -3.5 | -4.0 | -5.0 | -2.8 | -6.0 | -3.8 | -4.3 | -3.3 | -5.9 | -6.2 | -3.9 | -5.2 | -3.3 | -1.1 | -3.1 | -5.4 | -2.9 | -1.6 | 0.0 | 0.3 | 3.5 | 4.0 | 0.9 | 0.0 | 2.3 |
| Saxagliptin 2.5 mg | -1.0 | -1.9 | -1.5 | -3.0 | -3.6 | -3.3 | -4.9 | -3.2 | -5.1 | -5.0 | -6.1 | -2.8 | -3.6 | -3.0 | -2.5 | -1.2 | -2.9 | -2.8 | -0.6 | -2.6 | -5.1 | -1.8 | -0.8 | 0.7 | 0.9 | 3.4 | 4.8 |
| Saxagliptin 5 mg | -2.0 | -1.2 | -2.1 | -1.8 | -2.9 | -2.9 | -2.0 | -2.1 | -0.9 | -3.2 | -4.5 | -4.1 | -3.8 | -3.5 | 0.1 | -0.3 | -2.6 | -3.4 | -1.1 | -2.6 | -5.5 | -5.2 | -0.5 | -1.8 | -5.4 | -7.5 | -2.8 |
(NCT00121641)
Timeframe: Baseline, Weeks 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 30, 37, 50, 63, 76, 89, 102, 115, 128, 141, 154, 167
| Intervention | mmHg (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change from BL at Week 2 (n=62) | Change from BL at Week 4 (n=59) | Change from BL at Week 6 (n=60) | Change from BL at Week 8 (n=49) | Change from BL at Week 10 (n=24) | Change from BL at Week 12 (n=47) | Change from BL at Week 14 (n=35) | Change from BL at Week 16 (n=46) | Change from BL at Week 18 (n=42) | Change from BL at Week 20 (n=45) | Change from BL at Week 22 (n=44) | Change from BL at Week 24 (n=44) | Change from BL at Week 30 (n=40) | Change from BL at Week 37 (n=35) | Change from BL at Week 50 (n=36) | Change from BL at Week 63 (n=26) | Change from BL at Week 76 (n=24) | Change from BL at Week 89 (n=23) | Change from BL at Week 102 (n=15) | Change from BL at Week 115 (n=13) | Change from BL at Week 128 (n=11) | Change from BL at Week 141 (n=10) | Change from BL at Week 154 (n=10) | Change from BL at Week 167 (n=10) | |
| Open-Label Treatment Cohort (Direct Enrollees) | -4.4 | -3.8 | -2.7 | -5.1 | -4.2 | -4.9 | -5.1 | -1.9 | -5.8 | -3.6 | -4.0 | -4.3 | -4.8 | -4.7 | -1.6 | -0.7 | -1.9 | -4.0 | 0.9 | -6.6 | -5.6 | -7.2 | 5.7 | -2.2 |
The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal BL, Normal Week 12 (BL n=65, 66, 67, 47) | Normal BL, Abnormal Week 12 (BL n=65, 66, 67, 47) | Abnormal BL, Normal Week 12 (BL n=27, 32, 26, 43) | Abnormal BL, Abnormal Week 12(BL n=27, 32, 26, 43) | Normal BL, Normal Week 24 (BL n=53, 52, 47, 33) | Normal BL, Abnormal Week 24 (BL n=53, 52, 47, 33) | Abnormal BL, Normal Week 24 (BL n=19, 24, 21, 25) | Abnormal BL, Abnormal Week 24(BL n=19, 24, 21, 25) | Normal BL, Normal Week 76 (BL n=48, 49, 48, 36) | Normal BL, Abnormal Week 76 (BL n=48, 49, 48, 36) | Abnormal BL, Normal Week 76 (BL n=19, 23, 21, 27) | Abnormal BL, Abnormal Week 76(BL n=19, 23, 21, 27) | Normal BL, Normal Week 102 (BL n=32, 32, 36, 22) | Normal BL, Abnormal Week 102 (BL n=32, 32, 36, 22) | Abnormal BL, Normal Week 102 (BL n=12, 18, 17, 20) | Abnormal BL,Abnormal Week 102(BL n=12, 18, 17, 20) | Normal BL, Normal Week 154 (BL n=20, 21, 26, 15) | Normal BL, Abnormal Week 154 (BL n=20, 21, 26, 15) | Abnormal BL, Normal Week 154 (BL n=7, 16, 11, 13) | Abnormal BL, Abnormal Week 154(BL n=7, 16, 11, 13) | Normal BL, Normal Week 206 (BL n=15, 13, 20, 14) | Normal BL, Abnormal Week 206 (BL n=15, 13, 20, 14) | Abnormal BL, Normal Week 206 (BL n=4, 13, 8, 11) | Abnormal BL, Abnormal Week 206 (BL n=4, 13, 8, 11) | |
| Placebo | 43 | 4 | 15 | 28 | 31 | 2 | 8 | 17 | 30 | 6 | 13 | 14 | 18 | 4 | 11 | 9 | 14 | 1 | 7 | 6 | 11 | 3 | 4 | 7 |
| Saxagliptin 10 mg | 59 | 8 | 9 | 17 | 43 | 4 | 9 | 12 | 40 | 8 | 6 | 15 | 31 | 5 | 12 | 5 | 23 | 3 | 5 | 6 | 18 | 2 | 4 | 4 |
| Saxagliptin 2.5 mg | 57 | 8 | 6 | 21 | 43 | 10 | 5 | 14 | 37 | 11 | 8 | 11 | 25 | 7 | 4 | 8 | 16 | 4 | 4 | 3 | 15 | 0 | 2 | 2 |
| Saxagliptin 5 mg | 56 | 10 | 6 | 26 | 44 | 8 | 8 | 16 | 44 | 5 | 8 | 15 | 26 | 6 | 5 | 13 | 17 | 4 | 4 | 12 | 12 | 1 | 3 | 10 |
The normality/abnormality of the ECG tracing was determined by the investigator. (NCT00121641)
Timeframe: Baseline, Weeks 12, 24, 76, 102, 154, 206
| Intervention | participants (Number) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal BL, Normal Week 12 (BL n=23) | Normal BL, Abnormal Week 12 (BL n=23) | Abnormal BL, Normal Week 12 (BL n=18) | Abnormal BL, Abnormal Week 12 (BL n=18) | Normal BL, Normal Week 24 (BL n=10) | Normal BL, Abnormal Week 24 (BL n=10) | Abnormal BL, Normal Week 24 (BL n=6) | Abnormal BL, Abnormal Week 24(BL n=6) | Normal BL, Normal Week 76 (BL n=17) | Normal BL, Abnormal Week 76 (BL n=17) | Abnormal BL, Normal Week 76 (BL n=13) | Abnormal BL, Abnormal Week 76 (BL n=13) | Normal BL, Normal Week 102 (BL n=8) | Normal BL, Abnormal Week 102 (BL n=8) | Abnormal BL, Normal Week 102 (BL n=4) | Abnormal BL, Abnormal Week 102 (BL n=4) | Normal BL, Normal Week 154 (BL n=4) | Normal BL, Abnormal Week 154 (BL n=4) | Abnormal BL, Normal Week 154 (BL n=2) | Abnormal BL, Abnormal Week 154 (BL n=2) | Normal BL, Normal Week 206 (BL n=3) | Normal BL, Abnormal Week 206 (BL n=3) | Abnormal BL, Normal Week 206 (BL n=1) | Abnormal BL, Abnormal Week 206 (BL n=1) | |
| Open-Label Treatment Cohort (Direct Enrollees) | 19 | 4 | 5 | 13 | 8 | 2 | 2 | 4 | 13 | 4 | 4 | 9 | 6 | 2 | 1 | 3 | 3 | 1 | 0 | 2 | 2 | 1 | 0 | 1 |
To compare the change from baseline in HbA1c achieved with each dose of saxagliptin versus placebo in treatment naive subjects with type 2 diabetes who have inadequate glycemic control defined as A1C ≥7.0% and ≤10.0%. (NCT00121641)
Timeframe: Baseline, Week 24
| Intervention | Percentage of glycosylated hemoglobins (Mean) | |
|---|---|---|
| Baseline Mean | Adjusted Mean Change from Baseline | |
| Placebo | 7.88 | 0.19 |
| Saxagliptin 10 mg | 7.85 | -0.54 |
| Saxagliptin 2.5 mg | 7.91 | -0.43 |
| Saxagliptin 5 mg | 7.98 | -0.46 |
A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin < 8 g/dL (n=101, 105, 97, 93) | Hematocrit < 0.75 x pre-Rx (n=101, 105, 97, 93) | Platelets < 50 x 10^9 c/L (n=100, 104, 94, 93) | Platelets > 1.5 x ULN (n=100,104, 94, 93) | Leukocytes < 2 x 1000 c/µL (n=101, 105, 97, 93) | Neutrophils+Bands <1x1000 c/µL(n=101, 105, 97, 93) | Eosinophils >0.9x1000 c/µL (n=101, 105, 97, 93) | Lymphocytes <=0.75x1000 c/µL (n=101, 105, 97, 93) | ALP >3 x pre-Rx and >ULN (n=101,105, 97, 94) | ALP >1.5 x ULN (n=101, 105, 97, 94) | AST >3 x ULN (n=101, 105, 97, 94) | AST >5 x ULN (n=101, 105, 97, 94) | AST >10 x ULN (n=101, 105, 97, 94) | AST >20 x ULN (n=101, 105, 97, 94) | ALT >3 x ULN (n=101, 105, 97, 94) | ALT >5 x ULN (n=101, 105, 97, 94) | ALT >10 x ULN (n=101, 105, 97, 94) | ALT >20 x ULN (n=101, 105, 97, 94) | Bilirubin Total >2mg/dL (n=101, 105, 97, 94) | Bilirubin Total >1.5xULN (n=101, 105, 97, 94) | Bilirubin Total >2xULN (n=101, 105, 97, 94) | BUN >2 x pre-Rx and >ULN (n=101, 105, 97, 94) | Creatinine >2.5 mg/dL (n=101, 105, 97, 94) | Glucose, Serum Fasting < 50 mg/dL (n=0, 0, 0, 0) | Glucose, Serum Fasting > 500 mg/dL (n=0, 0, 0, 0) | Glucose, Serum Unspec. < 50 mg/dL (n=0,0,0,0) | Glucose, Serum Unspec. > 500 mg/dL (n=0,0,0,0) | Glucose, Plasma Fasting<50mg/dL(n=101, 104, 96,94) | Glucose,Plasma Fasting>500mg/dL(n=101, 104, 96,94) | Glucose, Plasma Unspec.<50mg/dL(n=102, 105, 98,95) | Glucose,Plasma Unspec.>500mg/dL(n=102, 105, 98,95) | Sodium,Serum Low (see above) (n=101, 105, 97, 94) | Sodium,Serum High(see above) (n=101, 105, 97, 94) | Potassium,Serum Low(see above)(n=101, 105, 97, 94) | Potassium, Serum High(see above)(n=101,105,97,94) | Chloride < 90 mEq/L (n=101, 105, 97, 94) | Chloride > 120 mEq/L (n=101, 105, 97, 94) | Albumin < 0.9 LLN (n=101, 105, 97, 94) | Creatine Kinase > 5 x ULN (n=101, 105, 97, 94) | Uric Acid > 1.5 x ULN (n=0, 0, 0, 0) | Protein Urine, >=2-4 (n=99, 103, 94, 92) | Blood Urine, >=2-4 (n=99, 103, 94, 92) | Red Blood Cells Urine >=2-4 (n=95, 97, 89, 88) | White Blood Cells Urine >=2-4 (n=95, 97, 89, 88) | |
| Placebo | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 3 | 2 | 1 | 0 | 0 | 3 | 1 | 0 | 0 | 4 | 0 | 3 | 16 | 14 | 12 |
| Saxagliptin 10 mg | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 2 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 4 | 8 | 8 | 15 |
| Saxagliptin 2.5 mg | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 4 | 0 | 2 | 3 | 2 | 1 | 0 | 3 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 7 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 8 | 5 | 6 | 13 |
| Saxagliptin 5 mg | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4 | 0 | 9 | 11 | 8 | 19 |
A laboratory value was considered a marked abnormality if it is outside the pre-defined criteria for marked abnormality and the on-treatment value was more extreme (farther from the limit) than the baseline value. Pre-Rx=pretreatment; ULN=upper limit of normal; ALP=alkaline phosphatase; AST=aspartate aminotransferase; ALT=alanine aminotransferase; unspec=unspecified; sodium serum low: <0.9 x Pre-Rx & <=130mEq/L / high: >1.1 x Pre-Rx & >=150mEq/L; potassium, serum low: <=0.8 x Pre-Rx & >=6.0mEq/L / high: 1.2 x Pre-Rx & >=6.0mEq/L; LLN=lower limit of normal. (NCT00121641)
Timeframe: Lab assessments taken during and up to 14 days after the last dose of study drug during the ST + LT Treatment Period. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin < 8 g/dL (n=64) | Hematocrit < 0.75 x pre-Rx (n=64) | Platelets < 50 x 10^9 c/L (n=64) | Platelets > 1.5 x ULN (n=64) | Leukocytes < 2 x 1000 c/µL (n=64) | Neutrophils+Bands <1x1000 c/uL (n=64) | Eosinophils >0.9x1000 c/µL (n=64) | Lymphocytes <=0.75x1000 c/uL (n=64) | ALP >3 x pre-Rx and >ULN (n=64) | ALP >1.5 x ULN (n=64) | AST >3 x ULN (n=64) | AST >5 x ULN (n=64) | AST >10 x ULN (n=64) | AST >20 x ULN (n=64) | ALT >3 x ULN (n=64) | ALT >5 x ULN (n=64) | ALT >10 x ULN (n=64) | ALT >20 x ULN (n=64) | Bilirubin Total >2mg/dL (n=64) | Bilirubin Total >1.5xULN (n=64) | Bilirubin Total >2xULN (n=64) | BUN >2 x pre-Rx and >ULN (n=64) | Creatinine >2.5 mg/dL (n=64) | Glucose, Serum Fasting < 50 mg/dL (n=1) | Glucose, Serum Fasting > 500 mg/dL (n=1) | Glucose, Serum Unspec. < 50 mg/dL (n=1) | Glucose, Serum Unspec. > 500 mg/dL (n=1) | Glucose, Plasma Fasting <50 mg/dL (n=64) | Glucose,Plasma Fasting >500 mg/dL (n=64) | Glucose, Plasma Unspec. <50 mg/dL (n=65) | Glucose,Plasma Unspec. >500 mg/dL (n=65) | Sodium,Serum Low (see above) (n=65) | Sodium,Serum High (see above) (n=65) | Potassium,Serum Low (see above) (n=65) | Potassium, Serum High (see above) (n=65) | Chloride < 90 mEq/L (n=65) | Chloride > 120 mEq/L (n=65) | Albumin < 0.9 LLN (n=64) | Creatine Kinase > 5 x ULN (n=64) | Uric Acid > 1.5 x ULN (n=0) | Protein Urine, >=2-4 (n=64) | Blood Urine, >=2-4 (n=64) | Red Blood Cells Urine >=2-4 (n=58) | White Blood Cells Urine >=2-4 (n=58) | |
| Open-Label Treatment Cohort (Direct Enrollees) | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 2 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 4 | 7 | 6 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 109 weeks in 10 mg arm, 94.7 weeks in 2.5 mg arm, 103 weeks in 5 mg arm, and 98.4 weeks in placebo arm.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At Least 1 AE | At Least 1 Related AE | Deaths | At Least 1 SAE | At Least 1 Related SAE | Discontinuations Due to SAEs | Discontinuations Due to AEs | |
| Placebo | 77 | 25 | 1 | 11 | 0 | 1 | 5 |
| Saxagliptin 10 mg | 87 | 25 | 0 | 9 | 0 | 3 | 10 |
| Saxagliptin 2.5 mg | 89 | 25 | 0 | 11 | 0 | 6 | 9 |
| Saxagliptin 5 mg | 94 | 23 | 0 | 18 | 1 | 2 | 10 |
AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, results in development of drug dependency or drug abuse, is an important medical event. Related events=relationship of certain, probable, possible, or missing. (NCT00121641)
Timeframe: AEs: up to last treatment day + 1 day or last visit; SAEs: up to last treatment day + 30 days or last visit + 30 days. Mean duration of exposure was 34 weeks.
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At Least 1 AE | At Least 1 Related AE | Deaths | At Least 1 SAE | At Least 1 Related SAE | Discontinuations Due to SAEs | Discontinuations Due to AEs | |
| Open-Label Treatment Cohort (Direct Enrollees) | 49 | 9 | 0 | 6 | 0 | 2 | 5 |
"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated following the data-driven method by Marquart et al. (2015), removing potential lag and tail phases prior to log-linear regression modeling." (NCT02223871)
Timeframe: 48 hours after study drug administration
| Intervention | Ratio (Mean) |
|---|---|
| ACT-451840 500 mg | 73.6 |
"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.~The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated using an objective standardized approach (observed data over 48 h)" (NCT02223871)
Timeframe: 48 hours after study drug administration
| Intervention | Ratio (Mean) |
|---|---|
| ACT-451840 500 mg | 234.5 |
Cmax was directly derived from the plasma concentrations-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to 144 hours after study drug adminsitration
| Intervention | ng/mL (Geometric Mean) |
|---|---|
| ACT-451840 500 mg | 121.7 |
Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug adminsitration
| Intervention | Hours (Geometric Mean) |
|---|---|
| ACT-451840 500 mg | 36.4 |
tmax was directly derived from the plasma concentration-time curves of ACT-451840. Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose. (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration
| Intervention | Hours (Median) |
|---|---|
| ACT-451840 500 mg | 4.0 |
"Two AUCs were calculated using non-compartmental analysis: AUC(0-t) from pre-dose to last time-point of measure and AUC(0-inf) from pre-dose and extrapolated to infinity.~Blood samples for pharmacokinetic characterization were drawn at pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 14, 16, 20, 24, 48, 72, 96, and 144 hours post-dose" (NCT02223871)
Timeframe: From pre-dose to144 hours after study drug administration
| Intervention | ng*h/mL (Geometric Mean) | |
|---|---|---|
| AUC(0-t) | AUC(0-inf) | |
| ACT-451840 500 mg | 1254.8 | 1284.4 |
Vital signs, including diastolic and systolic blood pressure (DBP/SBP), were measured at each outpatient visit up to 7 days after ACT-451840 administration, every day during confinement or when malaria symptoms were presented and at the end of study visit (EOS). Other measures were performed if required. (NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | mmHg (Median) | |||||
|---|---|---|---|---|---|---|
| SBP at baseline (Day 0) | SBP at EOS (Day 28) | Change from Day 0 to Day 28 in SBP | DBP at baseline (Day 0) | DBP at EOS (Day 28) | Change from Day 0 to Day 28 in DBP | |
| ACT-451840 500 mg | 121.0 | 125.5 | 2.5 | 66.0 | 70.5 | 0.5 |
Body temperature was measured orally (NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | Degree Celsius (Median) | ||
|---|---|---|---|
| Temperature at baseline (Day 0) | Temperature at EOS (Day 28) | Change from Day 0 to Day 28 in temperature | |
| ACT-451840 500 mg | 36.3 | 35.9 | -0.2 |
(NCT02223871)
Timeframe: Day 28 (EOS)
| Intervention | Breaths/min (Median) | ||
|---|---|---|---|
| Respiratory rate at baseline (Day 0) | Respiratory rate at EOS (Day 28) | Change from Day 0 to Day 28 in respiratory rate | |
| ACT-451840 500 mg | 14 | 16 | 1.5 |
Any treatment for malaria meeting criteria for severe malaria or danger signs (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.022 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.024 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.000 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.035 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.000 |
Admission to a hospital for pediatric inpatient care for any reason (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.043 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.036 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.089 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.082 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.043 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at 24 months of age and will end when study participants reaches 36 months of age or termination
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.87 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.88 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.83 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 1.24 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.64 |
Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age. (NCT02163447)
Timeframe: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age)
| Intervention | Events per person years (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 0.26 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 0.30 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0.00 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 0.43 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0.03 |
Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. (NCT02163447)
Timeframe: Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination
| Intervention | events per person years (Number) |
|---|---|
| Mothers - 3 Dose SP | 0.95 |
| Mothers - 3 Dose DP | 0.31 |
| Mothers - Monthly DP | 0 |
Congenital malformations, spontaneous abortion, LBW (<2500g), still birth, pre-term delivery (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 19 |
| Mothers - 3 Dose DP | 19 |
| Mothers - Monthly DP | 9 |
Prevalence of routine hemoglobin measurements < 11 g/dL (NCT02163447)
Timeframe: After first dose of study drugs up to delivery or early termination
| Intervention | hemoglobin measurements taken every 12wk (Number) |
|---|---|
| Mothers - 3 Dose SP | 94 |
| Mothers - 3 Dose DP | 72 |
| Mothers - Monthly DP | 61 |
Proportion of routine blood smears positive for gametocytes (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 7 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 1 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 0 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 4 |
| Monthly DP Pregnancy / Monthly DP Infancy | 0 |
Proportion of urgent blood smears positive for gametocytes (NCT02163447)
Timeframe: Gestational age between 12-20 weeks (at study entry) up to delivery
| Intervention | Positive blood smears (Number) |
|---|---|
| Mothers - 3 Dose SP | 4 |
| Mothers - 3 Dose DP | 1 |
| Mothers - Monthly DP | 3 |
Detection of malaria parasites by LAMP during pregnancy (NCT02163447)
Timeframe: After first dose of study drug through delivery or early termination
| Intervention | Positive specimens (Number) |
|---|---|
| Mothers - 3 Dose SP | 206 |
| Mothers - 3 Dose DP | 74 |
| Mothers - Monthly DP | 26 |
Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites. (NCT02163447)
Timeframe: Birth up to 24 months of age or early study termination
| Intervention | Positive blood smears (Number) |
|---|---|
| 3 Dose SP Pregnancy / 3 Monthly DP Infancy | 59 |
| 3 Dose DP Pregnancy / 3 Monthly DP Infancy | 25 |
| 3 Dose DP Pregnancy / Monthly DP Infancy | 7 |
| Monthly DP Pregnancy / 3 Monthly DP Infancy | 52 |
| Monthly DP Pregnancy / Monthly DP Infancy | 4 |
Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria. (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Mothers - 3 Dose SP | 49 |
| Mothers - 3 Dose DP | 30 |
| Mothers - Monthly DP | 26 |
Prevalence of placental blood samples positive for parasites by microscopy or LAMP (NCT02163447)
Timeframe: Delivery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Micropscopic assessment of placental blood | LAMP assessment of placental blood | |
| Mothers - 3 Dose DP | 3 | 3 |
| Mothers - 3 Dose SP | 5 | 19 |
| Mothers - Monthly DP | 0 | 2 |
Prevalence of maternal parasitemia at delivery by microscopy and LAMP (NCT02163447)
Timeframe: At delivery
| Intervention | participants (Number) | |
|---|---|---|
| Microscopy | LAMP | |
| Mothers - 3 Dose DP | 1 | 3 |
| Mothers - 3 Dose SP | 5 | 25 |
| Mothers - Monthly DP | 0 | 1 |
Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more (NCT03143218)
Timeframe: Passive surveillance of clinical episodes of malaria within the study area starting from the date of the first dose of study vaccines (April/May 2017) until 31st March 2020- a total of 36 months.
| Intervention | No. of events/1000 person years at risk (Number) |
|---|---|
| SMC With SP+AQ | 304.8 |
| RTS,S/AS01 | 278.2 |
| RTS,S/AS01 PLUS SMC With SP+AQ | 113.3 |
9 reviews available for pyrimethamine and Parasitemia
| Article | Year |
|---|---|
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Topics: Anemia; Antimalarials; Birth Weight; Child; Child, Preschool; Dietary Supplements; Female; Folic Aci | 2022 |
Drug treatment and prevention of malaria in pregnancy: a critical review of the guidelines.
Topics: Adult; Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Artesunate; Chloroquine | 2021 |
Intermittent preventive treatment for malaria in infants.
Topics: Africa South of the Sahara; Amodiaquine; Antimalarials; Artemisinins; Bias; Confidence Intervals; Di | 2021 |
Mefloquine for preventing malaria in pregnant women.
Topics: Abortion, Spontaneous; Africa South of the Sahara; Antimalarials; Dizziness; Drug Combinations; Drug | 2018 |
Mefloquine for preventing malaria in pregnant women.
Topics: Anemia; Antimalarials; Drug Combinations; Drug Therapy, Combination; Female; HIV Seronegativity; Hum | 2018 |
A systematic review and meta-analysis of dihydroartemisinin-piperaquine versus sulphadoxine-pyrimethamine for malaria prevention in pregnancy.
Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Drug Therapy, Combination; Female; Humans; Ma | 2019 |
Artemisinin-based combination therapy for treating uncomplicated Plasmodium vivax malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Drug Combinations; Drug Resi | 2013 |
Pregnancy-associated malaria and malaria in infants: an old problem with present consequences.
Topics: Adult; Africa South of the Sahara; Antimalarials; Comorbidity; Complement Activation; Developmental | 2014 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines | 2009 |
78 trials available for pyrimethamine and Parasitemia
| Article | Year |
|---|---|
The Impact of Antenatal Azithromycin and Monthly Sulfadoxine-Pyrimethamine on Maternal Malaria during Pregnancy and Fetal Growth: A Randomized Controlled Trial.
Topics: Antimalarials; Azithromycin; Drug Combinations; Female; Fetal Development; Humans; Malaria; Parasite | 2023 |
A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.
Topics: Adult; Antimalarials; Asymptomatic Diseases; Azithromycin; Chemoprevention; Drug Combinations; Eryth | 2019 |
The Effect of Intermittent Preventive Treatment of Malaria During Pregnancy and Placental Malaria on Infant Risk of Malaria.
Topics: Adult; Antimalarials; Artemisinins; Drug Combinations; Female; Humans; Infant; Malaria; Malawi; Para | 2022 |
Efficacies of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium falciparum malaria in an area of an unstable seasonal transmission in Sudan.
Topics: Adolescent; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Female; | 2017 |
Comparative study of mefloquine and sulphadoxine-pyrimethamine for malaria prevention among pregnant women with HIV in southwest Nigeria.
Topics: Adult; Antimalarials; Drug Combinations; Female; HIV Infections; Humans; Malaria; Mefloquine; Nigeri | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
Intermittent screening and treatment with artemether-lumefantrine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in pregnancy: a facility-based, open-label, non-inferiority trial in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Chemoprevention; Drug C | 2018 |
A randomized controlled trial of azithromycin and sulphadoxine-pyrimethamine as prophylaxis against malaria in pregnancy among human immunodeficiency virus-positive women.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Drug Combinations; Drug Therapy, Combinat | 2019 |
Nonrandomized controlled trial of artesunate plus sulfadoxine-pyrimethamine with or without primaquine for preventing posttreatment circulation of Plasmodium falciparum gametocytes.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Drug Combinations; Drug The | 2013 |
Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine during pregnancy in Burkina Faso: effect of adding a third dose to the standard two-dose regimen on low birth weight, anaemia and pregnancy outcomes.
Topics: Adolescent; Adult; Anemia; Antimalarials; Burkina Faso; Drug Combinations; Female; Humans; Infant, L | 2010 |
In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi.
Topics: Adolescent; Adult; Antimalarials; Asymptomatic Infections; Dihydropteroate Synthase; Drug Combinatio | 2015 |
Evaluating the pharmacodynamic effect of antimalarial drugs in clinical trials by quantitative PCR.
Topics: Adolescent; Adult; Algorithms; Antimalarials; Area Under Curve; Drug Combinations; Female; Half-Life | 2015 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Double-Blind Method; Drug Administration Schedule; D | 2016 |
Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
Topics: Adolescent; Anemia; Antimalarials; Chemoprevention; Child; Child, Preschool; Democratic Republic of | 2017 |
[Gametocytemia in falciparum malaria treated with amodiaquine or artesunate].
Topics: Adolescent; Adult; Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Child, Preschool; | 2008 |
A randomized, controlled trial of intermittent preventive treatment with sulfadoxine-pyrimethamine, amodiaquine, or the combination in pregnant women in Ghana.
Topics: Amodiaquine; Anemia; Animals; Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Comb | 2008 |
Individual efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine in primi- and secundigravidae in rural Burkina Faso: impact on parasitaemia, anaemia and birth weight.
Topics: Adult; Anemia; Animals; Antimalarials; Birth Weight; Burkina Faso; Drug Combinations; Female; Humans | 2009 |
Short report: comparison of chlorproguanil-dapsone with a combination of sulfadoxine-pyrimethamine and chloroquine in children with malaria in northcentral Nigeria.
Topics: Animals; Antimalarials; Child, Preschool; Chloroquine; Dapsone; Drug Combinations; Drug Therapy, Com | 2009 |
Submicroscopic gametocytes and the transmission of antifolate-resistant Plasmodium falciparum in Western Kenya.
Topics: Animals; Artemisinins; Artesunate; Carrier State; Child, Preschool; Drug Combinations; Drug Resistan | 2009 |
Intermittent preventive treatment using artemisinin-based combination therapy reduces malaria morbidity among school-aged children in Mali.
Topics: Adolescent; Anemia; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combination; F | 2009 |
Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Blood; Chloroquine; Drug Combinations; Huma | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Presumptive treatment with sulphadoxine-pyrimethamine versus weekly chloroquine for malaria prophylaxis in children with sickle cell anaemia in Uganda: a randomized controlled trial.
Topics: Anemia, Sickle Cell; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Administration Schedu | 2009 |
Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon.
Topics: Administration, Oral; Amodiaquine; Antimalarials; Artemisinins; Cameroon; Child, Preschool; Drug Adm | 2010 |
The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso.
Topics: Age Distribution; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Fa | 2010 |
Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial.
Topics: Amodiaquine; Anemia; Antimalarials; Body Weight; Child, Preschool; Drug Administration Schedule; Dru | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Artemisinins; Artesunate; Child; Child, P | 2011 |
Impact of combining intermittent preventive treatment with home management of malaria in children less than 10 years in a rural area of Senegal: a cluster randomized trial.
Topics: Amodiaquine; Anemia; Animals; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; C | 2011 |
Efficacy of different primaquine-based antimalarial regimens against Plasmodium falciparum gametocytemia.
Topics: Adolescent; Adult; Aged; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Prescho | 2012 |
Treatment failure of pyrimethamine-sulphadoxine and induction of Plasmodium falciparum gametocytaemia in children in western Kenya.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug | 2003 |
Plasmodium falciparum gametocytaemia in Nigerian children: before, during and after treatment with antimalarial drugs.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2003 |
The efficacy of chloroquine, sulfadoxine-pyrimethamine and a combination of both for the treatment of uncomplicated Plasmodium falciparum malaria in an area of low transmission in western Uganda.
Topics: Adolescent; Adult; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Resi | 2004 |
Open randomized study of pyrimethamine-sulphadoxine vs. pyrimethamine-sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children.
Topics: Acute Disease; Antimalarials; Child; Child, Preschool; Drug Combinations; Drug Interactions; Drug Re | 2004 |
Efficacy of pyrimethamine-sulfadoxine in young children with uncomplicated falciparum malaria in rural Burkina Faso.
Topics: Antimalarials; Burkina Faso; Child, Preschool; Cohort Studies; Drug Combinations; Female; Humans; In | 2004 |
Risk factors for gametocyte carriage in uncomplicated falciparum malaria in children.
Topics: Amodiaquine; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Chloroquine; Chlorpheni | 2004 |
Impact of a double dose of sulphadoxine-pyrimethamine to reduce prevalence of pregnancy malaria in southern Mozambique.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Double-Blind Method; Drug Administration Schedule; D | 2004 |
Plasmodium falciparum hyperparasitaemia in children. Risk factors, treatment outcomes, and gametocytaemia following treatment.
Topics: Age Factors; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combina | 2004 |
Comparison of intermittent preventive treatment with chemoprophylaxis for the prevention of malaria during pregnancy in Mali.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anemia; Birth Weight; Chemoprevention; Chloroquine; Drug A | 2005 |
A randomized comparative study of chloroquine, amodiaquine and sulphadoxine-pyrimethamine for the treatment of uncomplicated malaria in Ghana.
Topics: Amodiaquine; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Female; Fever; Ghana; | 2005 |
Comparison of sulfadoxine-pyrimethamine with and without chloroquine for uncomplicated malaria in Nigeria.
Topics: Adolescent; Adult; Antimalarials; Body Weight; Child; Chloroquine; Drug Therapy, Combination; Female | 2005 |
Efficacy comparison between anti-malarial drugs in Africans presenting with mild malaria in the Central Republic of Africa: a preliminary study.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemisinins; Central African Republic; Drug Combinations | 2005 |
A comparison of the efficacy of artesunate plus sulfadoxine-pyrimethamine with that of sulfadoxine-pyrimethamine alone, in the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Combinations; Dru | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana.
Topics: Anemia; Antimalarials; Cluster Analysis; Drug Combinations; Ghana; Hospitalization; Humans; Incidenc | 2005 |
Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Chloroquine; Drug Com | 2005 |
[Evaluation of the therapeutic efficacy of amodiaquine versus chloroquine in the treatment of uncomplicated malaria in Abie, Côte-d'Ivoire].
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Cote d'Ivoire; Drug Combinations | 2005 |
(Sub)microscopic Plasmodium falciparum gametocytaemia in Kenyan children after treatment with sulphadoxine-pyrimethamine monotherapy or in combination with artesunate.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Carrier State; Child; Child, Preschool; Drug Combi | 2006 |
Lack of inhibition of the anti-malarial action of sulfadoxine-pyrimethamine by folic acid supplementation when used for intermittent preventive treatment in Gambian primigravidae.
Topics: Adolescent; Adult; Anemia; Animals; Antimalarials; Dietary Supplements; Drug Combinations; Female; F | 2006 |
Folic acid treatment of Zambian children with moderate to severe malaria anemia.
Topics: Anemia; Animals; Antimalarials; Atovaquone; Child; Child, Preschool; Drug Combinations; Folic Acid; | 2006 |
A randomized, placebo-controlled trial of intermittent preventive treatment with sulphadoxine-pyrimethamine in Gambian multigravidae.
Topics: Adolescent; Adult; Anemia; Antimalarials; Bedding and Linens; Drug Combinations; Female; Gambia; Gra | 2006 |
A randomised trial to assess the safety and efficacy of artemether-lumefantrine (Coartem) for the treatment of uncomplicated Plasmodium falciparum malaria in Rwanda.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child, Preschoo | 2007 |
A randomised, double-blind, placebo-controlled trial of atovaquone-proguanil vs. sulphadoxine-pyrimethamine in the treatment of malarial anaemia in Zambian children.
Topics: Anemia; Antimalarials; Atovaquone; Child; Child, Preschool; Double-Blind Method; Drug Combinations; | 2006 |
Continued efficacy of sulfadoxine-pyrimethamine as second line treatment for malaria in children in Guinea-Bissau.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Guinea-Bissa | 2006 |
Efficacies of artesunate plus either sulfadoxine-pyrimethamine or amodiaquine, for the treatment of uncomplicated, Plasmodium falciparum malaria in eastern Sudan.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Drug Comb | 2007 |
Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial.
Topics: Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Burkina Faso; C | 2007 |
Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Drug Combinations; Drug Therapy, Combinatio | 2007 |
Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesu | 2007 |
Intermittent preventive treatment of malaria in pregnancy: a community-based delivery system and its effect on parasitemia, anemia and low birth weight in Uganda.
Topics: Adolescent; Adult; Anemia; Antimalarials; Case-Control Studies; Community Health Workers; Drug Admin | 2008 |
A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women.
Topics: Adult; Animals; Antimalarials; Birth Weight; Chloroquine; Drug Combinations; Female; Hematocrit; Hum | 2007 |
Intermittent preventive treatment with sulphadoxine-pyrimethamine is effective in preventing maternal and placental malaria in Ibadan, south-western Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Dizziness; Drug Combinations; Female; Humans; Malari | 2007 |
Therapeutic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in southwestern Nigeria.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Child; | 2007 |
Inferiority of single-dose sulfadoxine-pyrimethamine intermittent preventive therapy for malaria during pregnancy among HIV-positive Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Two-dose versus monthly intermittent preventive treatment of malaria with sulfadoxine-pyrimethamine in HIV-seropositive pregnant Zambian women.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia; Antimalarials; Birth Weight; Double-Blind Meth | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Intermittent preventive treatment against malaria in infants in Gabon--a randomized, double-blind, placebo-controlled trial.
Topics: Anemia; Antimalarials; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; | 2007 |
Herba Artemisiae annuae tea preparation compared to sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria in adults: a randomized double-blind clinical trial.
Topics: Adult; Animals; Antimalarials; Artemisia annua; Double-Blind Method; Drug Combinations; Drugs, Chine | 2008 |
Specific and nonspecific responses to Plasmodium falciparum blood-stage parasites and observations on the gametocytemia in schoolchildren living in a malaria-endemic area of Mozambique.
Topics: Adolescent; Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Blotting, Western; C | 1995 |
The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi.
Topics: Analysis of Variance; Antimalarials; Chi-Square Distribution; Chloroquine; Drug Combinations; Drug T | 1994 |
Sulfadoxine/pyrimethamine or chloroquine/clindamycin treatment of Gabonese school children infected with chloroquine resistant malaria.
Topics: Adolescent; Animals; Anti-Bacterial Agents; Antimalarials; Child; Child, Preschool; Chloroquine; Cli | 1995 |
The effect of oral iron therapy during treatment for Plasmodium falciparum malaria with sulphadoxine-pyrimethamine on Malawian children under 5 years of age.
Topics: Antimalarials; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Follow-Up Studies; He | 1996 |
Responses of multidrug-resistant Plasmodium falciparum parasites to mefloquine in Nigerian children.
Topics: Animals; Anti-Infective Agents; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; | 1997 |
Chloroquine in Africa: critical assessment and recommendations for monitoring and evaluating chloroquine therapy efficacy in sub-Saharan Africa.
Topics: Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Monitoring; Drug Resistance; F | 1998 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial.
Topics: Anemia; Antimalarials; Bedding and Linens; Double-Blind Method; Drug Administration Schedule; Drug C | 1999 |
Population structure of recrudescent Plasmodium falciparum isolates from western Uganda.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antigens, Protozoan; Antimalarials; Child; Chil | 1999 |
Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Child, Preschool; Double-Blind Method; Drug | 2000 |
Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug R | 1999 |
Comparative efficacy of chloroquine plus chlorpheniramine alone and in a sequential combination with sulfadoxine-pyrimethamine, for the treatment of acute, uncomplicated, falciparum malaria in children.
Topics: Animals; Antimalarials; Antipruritics; Child; Child, Preschool; Chloroquine; Chlorpheniramine; Drug | 2000 |
In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania.
Topics: Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Drug Resistance, Microbial; Female; Fe | 2000 |
Therapy of uncomplicated falciparum malaria: a randomized trial comparing artesunate plus sulfadoxine-pyrimethamine versus sulfadoxine-pyrimethamine alone in Irian Jaya, Indonesia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimalarials; Artemisini | 2001 |
Anemia of persistent malarial parasitemia in Nigerian children.
Topics: Anemia; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2001 |
Sulfadoxine-pyrimethamine monotherapy in Tanzanian children gives rapid parasite clearance but slow fever clearance that is improved by chloroquine in combination therapy.
Topics: Acetaminophen; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Dru | 2002 |
Pharmacokinetics of sequential and simultaneous treatment with the combination chloroquine and sulfadoxine-pyrimethamine in acute uncomplicated Plasmodium falciparum malaria in the Philippines.
Topics: Acute Disease; Adolescent; Adult; Antimalarials; Area Under Curve; Child; Chloroquine; Drug Administ | 2002 |
98 other studies available for pyrimethamine and Parasitemia
| Article | Year |
|---|---|
Discovery of new thienopyrimidinone derivatives displaying antimalarial properties toward both erythrocytic and hepatic stages of Plasmodium.
Topics: Animals; Antimalarials; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Eryth | 2015 |
Development and Optimization of a Selective Whole-Genome Amplification To Study Plasmodium ovale Spp.
Topics: Amino Acids; Endonucleases; Humans; Malaria; Parasitemia; Plasmodium ovale; Pyrimethamine; Recurrenc | 2022 |
Intermittent preventive treatment with Sulphadoxine-Pyrimethamine (IPTp-SP) is associated with protection against sub-microscopic P. falciparum infection in pregnant women during the low transmission dry season in southwestern Cameroon: A Semi - longitudi
Topics: Antimalarials; Birth Weight; Cameroon; Drug Combinations; Female; Humans; Infant, Newborn; Insectici | 2022 |
A new effective antiplasmodial compound: Nanoformulated pyrimethamine.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Compounding; Liver; Malaria; Male; Mice; Micell | 2020 |
The efficacy of intermittent preventive therapy in the eradication of peripheral and placental parasitemia in a malaria-endemic environment, as seen in a tertiary hospital in Abuja, Nigeria.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Cross-Sectional Studies; Drug Combinations; Female; | 2020 |
Sulfadoxine-pyrimethamine parasitological efficacy against Plasmodium falciparum among pregnant women and molecular markers of resistance in Zambia: an observational cohort study.
Topics: Adult; Antimalarials; Cohort Studies; Drug Combinations; Female; Genetic Markers; Humans; Malaria, F | 2021 |
Intermittent preventive treatment comparing two versus three doses of sulphadoxine pyrimethamine (IPTp-SP) in the prevention of anaemia in pregnancy in Ghana: A cross-sectional study.
Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Combinations; Educational Status; Female | 2021 |
In vivo antimalarial activity of a probiotic bacterium Lactobacillus sakei isolated from traditionally fermented milk in BALB/c mice infected with Plasmodium berghei ANKA.
Topics: Animals; Antimalarials; Cameroon; Chloroquine; Disease Models, Animal; Drug Combinations; Fermented | 2021 |
The Discovery of Novel Antimalarial Aminoxadiazoles as a Promising Nonendoperoxide Scaffold.
Topics: 2,2'-Dipyridyl; Animals; Antimalarials; Atovaquone; Chloroquine; Drug Design; Female; Humans; Hydraz | 2017 |
Effect of Adding Azithromycin to Seasonal Malaria Chemoprevention.
Topics: Amodiaquine; Anti-Bacterial Agents; Antimalarials; Azithromycin; Burkina Faso; Child Mortality; Chil | 2019 |
What is the Link between Malaria Prevention in Pregnancy and Neonatal Survival in Nigeria?
Topics: Adolescent; Adult; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combinations; Femal | 2019 |
High rates of parasite recrudescence following intermittent preventive treatment with sulphadoxine-pyrimethamine during pregnancy in Benin.
Topics: Adolescent; Adult; Antimalarials; Benin; Dihydropteroate Synthase; Drug Combinations; Female; Haplot | 2013 |
In vitro and in vivo antimalarial activity and cytotoxicity of extracts and fractions from the leaves, root-bark and stem-bark of Triclisia gilletii.
Topics: Animals; Antimalarials; Cell Line; Cell Survival; Chloroquine; Drug Resistance, Multiple; Humans; Ma | 2013 |
Treatment of pregnant BALB/c mice with sulphadoxine pyrimethamine or chloroquine abrogates Plasmodium berghei induced placental pathology.
Topics: Animals; Antimalarials; Antioxidants; Chloroquine; DNA Fragmentation; Drug Combinations; Female; Lip | 2014 |
Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on placental malaria, maternal anaemia and birthweight in areas with high and low malaria transmission intensity in Tanzania.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Drug Combinations; Female; Humans; Infant, Low Birth Wei | 2014 |
Submicroscopic malaria infection during pregnancy and the impact of intermittent preventive treatment.
Topics: Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Asymptomatic Diseases | 2014 |
Uptake of intermittent preventive treatment with sulphadoxine-pyrimethamine for malaria during pregnancy and pregnancy outcomes: a cross-sectional study in Geita district, North-Western Tanzania.
Topics: Adolescent; Adult; Antimalarials; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combinat | 2014 |
Comparative Study of Effectiveness and Resistance Profile of Chloroquine and Sulfadoxine-Pyrimethamine in Uncomplicated Plasmodium falciparum Malaria in Kolkata.
Topics: Adolescent; Adult; Antimalarials; Child; Chloroquine; Drug Combinations; Drug Resistance; Female; Hu | 2015 |
The risk of malaria in Ghanaian infants born to women managed in pregnancy with intermittent screening and treatment for malaria or intermittent preventive treatment with sulfadoxine/pyrimethamine.
Topics: Antimalarials; Drug Combinations; Female; Ghana; Humans; Infant; Infant, Newborn; Malaria; Male; Par | 2016 |
Decrease of microscopic Plasmodium falciparum infection prevalence during pregnancy following IPTp-SP implementation in urban cities of Gabon.
Topics: Adult; Anemia; Antimalarials; Birth Weight; Cities; Cross-Sectional Studies; Drug Combinations; Fema | 2016 |
Methylene blue inhibits lumefantrine-resistant Plasmodium berghei.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Drug-Related Side Effects and Adver | 2016 |
Predictors of antimalarial treatment failure in an area of unstable malaria transmission in eastern Sudan.
Topics: Adolescent; Age Factors; Antimalarials; Child; Child, Preschool; Chloroquine; Cross-Sectional Studie | 2009 |
Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests?
Topics: Adolescent; Animals; Artemisinins; Child; Child, Preschool; Cost-Benefit Analysis; Diagnostic Tests, | 2008 |
Costs and cost-effectiveness of delivering intermittent preventive treatment through schools in western Kenya.
Topics: Anemia; Antimalarials; Chemoprevention; Communicable Disease Control; Cost-Benefit Analysis; Drug Co | 2008 |
Implementation of intermittent preventive treatment in pregnancy with sulphadoxine/pyrimethamine (IPTp-SP) at a district health centre in rural Senegal.
Topics: Adolescent; Adult; Analysis of Variance; Antimalarials; Drug Combinations; Female; Humans; Infant, L | 2008 |
Antiplasmodial activity of root extract and fractions of Croton zambesicus.
Topics: Animals; Antimalarials; Chloroquine; Croton; Female; Lethal Dose 50; Malaria; Male; Mice; Parasitemi | 2009 |
Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity.
Topics: Adolescent; Animals; Antimalarials; Artemisinins; Carrier State; Child; Child, Preschool; Drug Combi | 2008 |
Sub-microscopic infections and long-term recrudescence of Plasmodium falciparum in Mozambican pregnant women.
Topics: Adult; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Drug Combinations; Female; Genotype | 2009 |
Community-based distribution of sulfadoxine-pyrimethamine for intermittent preventive treatment of malaria during pregnancy improved coverage but reduced antenatal attendance in southern Malawi.
Topics: Adolescent; Adult; Anemia; Antimalarials; Birth Weight; Community Health Services; Drug Combinations | 2009 |
Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Dapsone; Drug Synergism; Drug Therapy, Combination | 2009 |
Active case detection, treatment of falciparum malaria with combined chloroquine and sulphadoxine/pyrimethamine and vivax malaria with chloroquine and molecular markers of anti-malarial resistance in the Republic of Vanuatu.
Topics: Adolescent; Adult; Antigens, Protozoan; Antimalarials; Case-Control Studies; Child; Child, Preschool | 2010 |
Revisiting the circulation time of Plasmodium falciparum gametocytes: molecular detection methods to estimate the duration of gametocyte carriage and the effect of gametocytocidal drugs.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Art | 2010 |
Efficacy of intermittent preventive treatment with sulfadoxine-pyrimethamine on placental parasitemia in pregnant women in midwestern Nigeria.
Topics: Adult; Anemia; Antimalarials; Cohort Studies; Drug Combinations; Female; Humans; Infant, Low Birth W | 2011 |
Marked reduction in prevalence of malaria parasitemia and anemia in HIV-infected pregnant women taking cotrimoxazole with or without sulfadoxine-pyrimethamine intermittent preventive therapy during pregnancy in Malawi.
Topics: Adolescent; Adult; Anemia; Antimalarials; Chemoprevention; Cross-Sectional Studies; Drug Combination | 2011 |
Artemether-Lumefantrin (Coartem) and artesunate with sulfadoxine-pyrimethamine therapeutic efficacy in the treatment of uncomplicated malaria at Gilgel Gibe II (GGII) South-Western Ethiopia.
Topics: Adolescent; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Chil | 2010 |
Coverage of intermittent prevention treatment with sulphadoxine-pyrimethamine among pregnant women and congenital malaria in Côte d'Ivoire.
Topics: Adolescent; Adult; Chemoprevention; Cote d'Ivoire; Cross-Sectional Studies; Drug Combinations; Drug | 2011 |
Selection of drug resistant mutants from random library of Plasmodium falciparum dihydrofolate reductase in Plasmodium berghei model.
Topics: Animals; Antimalarials; Drug Resistance; Female; Folic Acid Antagonists; Gene Expression Regulation, | 2011 |
Prolonged elevation of viral loads in HIV-1-infected children in a region of intense malaria transmission in Northern Uganda: a prospective cohort study.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Chloroquine; Disease Progression; Drug | 2010 |
Quantification of the burden and consequences of pregnancy-associated malaria in the Democratic Republic of the Congo.
Topics: Anemia; Antimalarials; Birth Weight; Cross-Sectional Studies; Democratic Republic of the Congo; Drug | 2011 |
The effectiveness and perception of the use of sulphadoxine-pyrimethamine in intermittent preventive treatment of malaria in pregnancy programme in Offinso district of Ashanti region, Ghana.
Topics: Adult; Anemia; Antimalarials; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinatio | 2011 |
The impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on the prevalence of malaria parasitaemia in pregnancy.
Topics: Adult; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Malaria; Para | 2012 |
Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antimalarials; Cross-Sectional Studies; Drug Combinations | 2012 |
Routine delivery of artemisinin-based combination treatment at fixed health facilities reduces malaria prevalence in Tanzania: an observational study.
Topics: Adolescent; Adult; Antimalarials; Artemisinins; Child; Child, Preschool; Cross-Sectional Studies; Dr | 2012 |
Using community-owned resource persons to provide early diagnosis and treatment and estimate malaria burden at community level in north-eastern Tanzania.
Topics: Adolescent; Adult; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Blood; Ch | 2012 |
The effects of malaria and intermittent preventive treatment during pregnancy on fetal anemia in Malawi.
Topics: Anemia, Neonatal; Antimalarials; Cross-Sectional Studies; Drug Combinations; Female; Fetal Blood; Fe | 2012 |
A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.
Topics: Adolescent; Animals; Anopheles; Antimalarials; Child; Drug Combinations; Female; Humans; Insect Bite | 2002 |
Determinants of treatment response to sulfadoxine-pyrimethamine and subsequent transmission potential in falciparum malaria.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Child; Child, Preschool; Dihydropteroate Synthase; | 2002 |
Plasmodium berghei: routine production of pure gametocytes, extracellular gametes, zygotes, and ookinetes.
Topics: Animals; Antimalarials; Centrifugation; Erythrocytes; Female; Germ Cells; Malaria; Mice; Parasitemia | 2002 |
Increased efficacy of sulfadoxine-pyrimethamine in the treatment of uncomplicated falciparum malaria among children with sickle cell trait in Western Kenya.
Topics: Animals; Antimalarials; Child, Preschool; Drug Combinations; Female; Hemoglobin A; Hemoglobin, Sickl | 2002 |
In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Drug Resistance; Drug Resistance, Multiple; Humans | 2002 |
Malaria treated with daraprim, including cerebral malaria and high parasitaemia.
Topics: Malaria; Malaria, Cerebral; Parasitemia; Pyrimethamine; Pyrimidines | 1952 |
Therapeutic efficacies of antimalarial drugs in the treatment of uncomplicated, Plasmodium falciparum malaria in Assam, north-eastern India.
Topics: Adolescent; Adult; Aged; Animals; Anti-Infective Agents; Antimalarials; Artemisinins; Child; Child, | 2003 |
Drug resistance in Plasmodium falciparum from the Chittagong Hill Tracts, Bangladesh.
Topics: Adolescent; Adult; Animals; Antimalarials; ATP-Binding Cassette Transporters; Bangladesh; Child; Chi | 2004 |
Early treatment during a primary malaria infection modifies the development of cross immunity.
Topics: Animals; Antibodies, Protozoan; Body Weight; Cross Reactions; Gene Expression; Hemoglobins; Immunity | 2004 |
Plasmodium falciparum gametocyte carriage in asymptomatic children in western Kenya.
Topics: Adolescent; Age Factors; Animals; Antimalarials; Carrier State; Child; Child, Preschool; Cohort Stud | 2004 |
Malaria: use of restriction endonuclease digestion and mutation-specific PCR for antifolate resistance isolate detection.
Topics: Amino Acid Substitution; Animals; Antimalarials; DNA Mutational Analysis; DNA, Protozoan; Drug Resis | 2003 |
Monitoring susceptibility to sulfadoxine-pyrimethamine among cases of uncomplicated, Plasmodium falciparum malaria in Saharevo, Madagascar.
Topics: Animals; Antimalarials; Child; Child, Preschool; Drug Combinations; Female; Humans; Madagascar; Mala | 2004 |
Comparative effects of pyrimethamine-sulfadoxine, with and without probenecid, on Plasmodium falciparum gametocytes in children with acute, uncomplicated malaria.
Topics: Acute Disease; Animals; Antimalarials; Child; Drug Combinations; Drug Therapy, Combination; Endemic | 2004 |
Efficacy of amodiaquine in uncomplicated falciparum malaria in Nigeria in an area with high-level resistance to chloroquine and sulphadoxine/pyrimethamine.
Topics: Amodiaquine; Animals; Antimalarials; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistan | 2005 |
Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
Topics: Animals; Antimalarials; Child, Preschool; Dihydropteroate Synthase; Drug Combinations; Drug Resistan | 2005 |
Efficacy of sulfadoxine-pyrimethamine in Tanzania after two years as first-line drug for uncomplicated malaria: assessment protocol and implication for treatment policy strategies.
Topics: Animals; Antigens, Protozoan; Antimalarials; Body Temperature; Child, Preschool; Drug Combinations; | 2005 |
CD4 T cell activation as a predictor for treatment failure in Ugandans with Plasmodium falciparum malaria.
Topics: Adolescent; Adult; Age Factors; Animals; Antimalarials; Body Temperature; CD4-Positive T-Lymphocytes | 2006 |
Improved transfection and new selectable markers for the rodent malaria parasite Plasmodium yoelii.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Electroporation; Female; Green Fluo | 2006 |
Prevalence of malaria parasitemia among clients seeking treatment for fever or malaria at drug stores in rural Tanzania 2004.
Topics: Adult; Amodiaquine; Analgesics, Non-Narcotic; Anemia; Antimalarials; Child, Preschool; Drug Combinat | 2006 |
Microscopy and outpatient malaria case management among older children and adults in Kenya.
Topics: Adolescent; Adult; Ambulatory Care; Amodiaquine; Antimalarials; Case Management; Child; Cross-Sectio | 2006 |
The efficacy of sulfadoxine-pyrimethamine alone and in combination with chloroquine for malaria treatment in rural Eastern Sudan: the interrelation between resistance, age and gametocytogenesis.
Topics: Adolescent; Adult; Age Distribution; Antimalarials; Child; Chloroquine; Cohort Studies; Drug Combina | 2006 |
Malaria prevention during pregnancy: assessing the disease burden one year after implementing a program of intermittent preventive treatment in Koupela District, Burkina Faso.
Topics: Adolescent; Adult; Antimalarials; Bedding and Linens; Burkina Faso; Drug Combinations; Female; Human | 2006 |
Relationship between antipyretic effects and cytokine levels in uncomplicated falciparum malaria during different treatment regimes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Antimalarials; Child, Preschool; Chloroquine; Cyto | 2006 |
HIV immunosuppression and antimalarial efficacy: sulfadoxine-pyrimethamine for the treatment of uncomplicated malaria in HIV-infected adults in Siaya, Kenya.
Topics: Adult; Anemia; Antimalarials; CD4 Lymphocyte Count; Drug Combinations; Female; Fever; HIV Infections | 2006 |
In vitro and in vivo interaction of synthetic peroxide RBx11160 (OZ277) with piperaquine in Plasmodium models.
Topics: Animals; Antimalarials; Artemether; Artemisinins; Atovaquone; Disease Models, Animal; Drug Interacti | 2007 |
Assessing malaria burden during pregnancy in Mali.
Topics: Adult; Animals; Antimalarials; Chloroquine; Cross-Sectional Studies; Drug Combinations; Female; Huma | 2007 |
Malaria treatment efficacy among people living with HIV: the role of host and parasite factors.
Topics: Adolescent; Adult; Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Dru | 2007 |
Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria.
Topics: Adolescent; Adult; Animals; Antimalarials; Area Under Curve; Child; Dihydropteroate Synthase; Drug C | 2008 |
Impact of transmission intensity and age on Plasmodium falciparum density and associated fever: implications for malaria vaccine trial design.
Topics: Age Factors; Animals; Anopheles; Antimalarials; Child; Child, Preschool; Clinical Trials as Topic; C | 1995 |
Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa.
Topics: Animals; Base Sequence; Child; DNA Primers; DNA, Protozoan; Drug Resistance; Folic Acid Antagonists; | 1995 |
Sensitivity to antimalarial drugs by Plasmodium falciparum in Goundry, Oubritenga province, Burkina Faso.
Topics: Amodiaquine; Animals; Antimalarials; Burkina Faso; Child; Child, Preschool; Chloroquine; Drug Resist | 1994 |
Studies on ammonia-metabolizing enzymes during Plasmodium yoelii infection and pyrimethamine treatment in mice.
Topics: Alanine Transaminase; Ammonia; Animals; Antimalarials; Aspartate Aminotransferases; Biomarkers; Brai | 1996 |
Parasitemia and parasitic loads in acute infection and after anti-gamma-interferon treatment in a toxoplasmic mouse model.
Topics: Acute Disease; Animals; Anti-Infective Agents; Antibodies; Brain; Chronic Disease; Drug Therapy, Com | 1997 |
Parasitological and haematological responses to treatment of Plasmodium falciparum malaria with sulphadoxine-pyrimethamine in southern Malawi.
Topics: Anemia; Antimalarials; Child, Preschool; Drug Combinations; Female; Follow-Up Studies; Hemoglobins; | 1997 |
Gene targeting in malaria parasites.
Topics: Animals; Anopheles; Genes, Reporter; Genetic Vectors; Humans; Malaria; Parasitemia; Plasmids; Plasmo | 1997 |
Enhanced gametocyte production in Fansidar-treated Plasmodium falciparum malaria patients: implications for malaria transmission control programmes.
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Culicidae; Drug Combinations; Female; Humans; Inse | 1997 |
An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi.
Topics: Adolescent; Adult; Antimalarials; Birth Weight; Drug Therapy, Combination; Female; Humans; Infant, L | 1998 |
Studies on infections with two strains of Plasmodium inui from Taiwan in rhesus monkeys and different anopheline mosquitoes.
Topics: Animals; Anopheles; Antimalarials; Disease Models, Animal; Host-Parasite Interactions; Insect Vector | 1998 |
A systematic approach to the development of a rational malaria treatment policy in Zambia.
Topics: Antimalarials; Child; Child, Preschool; Chloroquine; Drug Combinations; Drug Evaluation; Drug Resist | 1998 |
In vivo responses to antimalarials by Plasmodium falciparum and Plasmodium vivax from isolated Gag Island off northwest Irian Jaya, Indonesia.
Topics: Adolescent; Adult; Age Distribution; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; D | 1999 |
Chemotherapy of malaria and resistance to antimalarial drugs in Guayana area, Venezuela.
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Chloroquine; Dose-Response Relationship, Drug; Drug | 1999 |
Plasmodium cynomolgi: transfection of blood-stage parasites using heterologous DNA constructs.
Topics: Animals; Antimalarials; Disease Models, Animal; DNA Primers; DNA, Protozoan; Drug Resistance; Electr | 1999 |
Pyrimethamine-sulfadoxine efficacy and selection for mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase in Mali.
Topics: Animals; Antimalarials; Blood; Child; Dihydropteroate Synthase; DNA Restriction Enzymes; DNA, Protoz | 1999 |
Association of the ICAM-1Kilifi mutation with protection against severe malaria in Lambaréné, Gabon.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Case-Control Studies; Child; Clindamycin; Deoxyribonu | 1999 |
Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Doxycycline; Erythromycin; | 2000 |
[Chloroquine sensitivity of Plasmodium falciparum at the Gamkalley Clinic and the Nigerian armed forces PMI (Niamey, Niger)].
Topics: Adolescent; Adult; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Hu | 1999 |
Population dynamics of Plasmodium falciparum in an unstable malaria area of eastern Sudan.
Topics: Alleles; Animals; Antigens, Protozoan; Antimalarials; Chloroquine; Cohort Studies; DNA Primers; DNA, | 2000 |
Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine.
Topics: Acetaminophen; Adolescent; Adult; Analgesics, Non-Narcotic; Animals; Anopheles; Antimalarials; Child | 2000 |
In vivo sensitivity of Plasmodium falciparum to chloroquine and sulfadoxine-pyrimethamine among schoolchildren in rural Uganda: a comparison between 1995 and 1998.
Topics: Animals; Antimalarials; Child; Chloroquine; Drug Combinations; Humans; Malaria, Falciparum; Parasite | 2000 |
Comparative clinical characteristics and response to oral antimalarial therapy of children with and without Plasmodium falciparum hyperparasitaemia in an endemic area.
Topics: Adolescent; Age Factors; Analysis of Variance; Antimalarials; Child; Child, Preschool; Chloroquine; | 2000 |
Diagnostic value of polymerase chain reaction in blood and aqueous humor in immunocompetent patients with ocular toxoplasmosis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antiprotozoal Agents; Aqueous Humor; Blotting, Southern; DN | 2000 |
Parasitaemia and gametocytaemia after treatment with chloroquine, pyrimethamine/sulfadoxine, and pyrimethamine/sulfadoxine combined with artesunate in young Gambians with uncomplicated malaria.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Child; Chloroquine; Cost-Benefit Analysis; Disease | 2001 |
[In vivo sensitivity of Plasmodium falciparum to amino-4-quinolines and sulfadoxine pyrimethamine in Agou (Ivory Coast)].
Topics: Adolescent; Aminoquinolines; Amodiaquine; Animals; Antimalarials; Child; Child, Preschool; Cote d'Iv | 2002 |